Europa Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Report Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) : 7.10 %

USD 273.07 Million USD 449.10 Million 2025 2033

Período de pronóstico	2026 –2033
Tamaño del mercado (año base)	USD 273.07 Million
Tamaño del mercado (año de pronóstico)	USD 449.10 Million
Tasa de crecimiento anual compuesta (CAGR)	7.10 %
Jugadoras de los principales mercados	Stanford Health Care (Estados Unidos) HOSPIRA (Ahora parte de Pfizer) (Estados Unidos) Aurora Health Care (Estados Unidos) Takeda Pharmaceutical Company Limited (Japón) Fresenius Kabi AG (Alemania)

Gestiones de Enfermedades Intensivas (Inteligencias Especiales), por Enfermedades de la Informática (Inteligencias Especiales), por Enfermedades de la Informática (Integridad)

Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)Tamaño

El tamaño del mercado de tratamiento de Europa tipo 1 SBS-IF (síndrome de tazón corto con falla intestinal) fue valorado en USD 273.07 Millones en 2025 y se espera que alcance USD 449.10 millones en 2033, en una CAGR de 7,1% durante el período de pronóstico. El mercado está presenciando un crecimiento constante debido a la creciente prevalencia del síndrome de intestino corto asociado con insuficiencia intestinal, la creciente conciencia de los trastornos gastrointestinales raros y los avances continuos en terapias nutricionales y farmacológicas especializadas. La creciente adopción de enfoques multidisciplinarios de tratamiento, junto con mejores capacidades de diagnóstico y mejores estrategias de gestión de pacientes, está apoyando aún más la expansión del mercado.

La creciente carga de las reseecciones intestinales como la enfermedad de Crohn, la isquemia mesentérica, el trauma, las anomalías congénitas y las cirugías relacionadas con el cáncer ha contribuido significativamente a la demanda de tratamientos tipo 1 SBS-IF. Los proveedores de atención médica están utilizando cada vez más la nutrición parenteral, el apoyo nutricional entral y las terapias analógicas del péptido-2 (GLP-2) para mejorar la adaptación intestinal, reducir las complicaciones y mejorar la calidad de vida del paciente.

Principales tendencias del mercado "Análisis

Alemania dominaba la Europa Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) Mercado de tratamiento con la mayor cuota de ingresos del 19,90% en 2025, apoyada por infraestructura sanitaria avanzada, políticas de reembolso sólidas y acceso generalizado a centros de rehabilitación intestinal especializados.
El segmento de la Terapia de Apoyo Nutricional llevó al mercado con una cuota de 41,87% en 2025, impulsada por su papel crítico en el mantenimiento de la hidratación, la absorción de nutrientes y la gestión general del paciente durante la recuperación intestinal.
Se espera que Dinamarca sea el país de mayor crecimiento en una CAGR de 9,1% de 2026 a 2033, alimentado por la mejora de la accesibilidad de la salud, el aumento de la conciencia de los trastornos gastrointestinales raros y el aumento de las inversiones en opciones avanzadas de tratamiento en las economías emergentes.
Las terapias emergentes y avanzadas son el segmento de la modalidad de tratamiento más rápido, proyectado para registrar un CAGR del 7,5%, lo que refleja una creciente adopción de biológicos innovadores, análogos GLP-2 y enfoques de tratamiento regenerativo dirigidos a reducir la dependencia de nutrición parenteral a largo plazo.
El segmento Core SBS-IF Market dominaba la categoría de atribución del mercado con una cuota de ingresos del 56,61% en 2025, con el apoyo de la población paciente sustancial que requería una gestión de falla intestinal especializada y continua.
El segmento de fase aguda (Tipo 1 SBS-IF) representó la mayor parte de 48,57% en 2025, impulsado por la necesidad inmediata de apoyo nutricional intensivo, manejo de fluidos e intervención clínica después de la resección o lesión intestinal principal.
Se prevé que el segmento de fase de adaptación sea la categoría de fase de mayor crecimiento, registrando un CAGR del 7,4% durante el período de previsión, debido a la creciente concentración en terapias que mejoran la adaptación intestinal, mejoran la absorción de nutrientes y apoyen la recuperación de pacientes a largo plazo.

Tamaño del mercado

Valor del mercado de Europa (2025): 273,07 dólares
Valor de mercado esperado (2033): USD 449,10 millones
CAGR prefabricado (2026–2033): 7,1%
País de cultivo más rápido: Dinamarca

Ámbito de presentación de informesTipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Atributos	Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)Market Insights
Segmentos cubiertos	Por Modalidad de Tratamiento:Terapia de Apoyo Nutricional, Terapia Farmacológica, Tratamiento Intervencional Quirúrgico y Terapias Avanzadas Emergentes Por Atribución al Mercado:Core SBS-IF Market, SBS-IF Atributable Market, y Adjacent / Non-Specific Market Por fase de gestión de enfermedades:fase aguda (Tipo 1 SBS-IF), fase de adaptación y fase de recuperación Por tipo de paciente:Adulto y Pediatría Por Ruta de Administración:Intravenosa, Subcutánea, Oral y Enteral Por tipo intravenoso:PN e inyectables Por Usuario Final:Hospitales (Acute Care), Home Care (HPN Programs), ICU Settings, Specialty GI Centers y Pediatric Specialty Hospitals Por Canal de Distribución:Farmacia Hospitalaria, Farmacia Especial, Farmacia Retail, y Farmacia Online
Países cubiertos	Europa · Alemania · Francia · U.K. · Países Bajos Suiza · Bélgica · Rusia · Italia · España · Turquía · El resto de Europa ·
Principales jugadores del mercado	• Nestle Health Science (Suiza) · Stanford Health Care (U.S.) · HOSPIRA (Ahora parte de Pfizer) (U.S.) · Cuidado de Salud Aurora (EE.UU.) · Takeda Pharmaceutical Company Limited (Japón) · Fresenius Kabi AG (Alemania) · Grifols (España) · Laboratorios Abbott (U.S.) · Shandong Qidu Pharmaceutical Co., Ltd. (China) · Ferring Pharmaceuticals (Suiza) · Salud UF (EE.UU.) · Baxter International INC (U.S.) · VectivBio AG (Suiza) · Hikma Pharmaceuticals PLC (Reino Unido) · NUTRICIA (DANONE) (Países Bajos) · Amsino International, Inc. (U.S.) · Braun Melsungen AG (Alemania) · ContinuumRx (U.S.) · JEDUX PARENTERAL PRIVATE LIMITED (India) · Beverly Hills Digestive Care (U.S.) · Elección de la Nutrición Parenteral LLC (U.S.) · Sistemas Integrados de Atención (U.S.) · Camvitaa (India) · Regenesis de Eclipse (U.S.) · LABORATOIRE DIELEN (Francia) · Vision Parenteral Pvt. Ltd. (India) · Atención de la salud aguda (India) · Nutrego (Polonia) · Pharmko, Inc. (U.S.) · Soluciones de infusión (U.S.) · Salud UF (EE.UU.) · Sistemas Integrados de Atención (U.S.) · Elección de la Nutrición Parenteral LLC (U.S.) · ContinuumRx (U.S.) · NUTRICIA NORTH AMERICA (U.S.) · Terapéutica Napo (U.S.) · una empresa Moog (U.S.) · ICU Medical, Inc. (U.S.) · Regenesis de Eclipse (U.S.) · Puerto Life Sciences Pvt. Ltd (India) · Bausch Health Companies (Canadá)
Oportunidades de mercado	· Avances en Medicina Regenerativa · Ampliación de la atención nutricional en el hogar
Valor añadido Data Infosets	Además de las ideas sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado comisariados por Data Bridge Market Research también incluyen análisis profundos de expertos, epidemiología de pacientes, análisis de tuberías, análisis de precios y marco regulatorio.

Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Tendencia: Manejo multidisciplinario complejo de pacientes

Los avances en la medicina regenerativa y la rehabilitación intestinal están creando fuertes oportunidades de crecimiento para el mercado de tratamiento Europa Tipo 1 SBS-IF. Los investigadores y las instituciones sanitarias se centran cada vez más en terapias que pueden mejorar la adaptación intestinal, regenerar el tejido intestinal dañado y reducir la dependencia a largo plazo de la nutrición parenteral. Según estudios apoyados por los Institutos Nacionales de Salud, enfoques regenerativos como terapia de células madre, ingeniería de tejidos e investigación de trasplantes intestinales están mostrando resultados prometedores para mejorar la absorción de nutrientes y restaurar la función intestinal en pacientes SBS-IF severos. Varios hospitales académicos y centros especializados de rehabilitación intestinal en América del Norte y Europa también están ampliando programas multidisciplinarios de tratamiento que combinan terapias GLP-2, apoyo nutricional avanzado, cirugía y planes de rehabilitación personalizados. Estos desarrollos están ayudando a mejorar la supervivencia del paciente y la calidad de vida a la vez que se abren nuevas oportunidades de tratamiento a largo plazo más allá de la gestión nutricional tradicional.

Europa Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal) Dinámica del mercado de tratamiento

Conductor del mercado clave: aumento del SBS-Si la población del paciente

La creciente población paciente que sufre de síndrome de Short Bowel con falla intestinal (SBS-IF) se está convirtiendo en uno de los principales factores de crecimiento para el mercado de tratamiento de Europa. SBS-IF se desarrolla principalmente cuando una gran parte del intestino delgado se elimina a través de la cirugía, reduciendo la capacidad del cuerpo para absorber nutrientes y líquidos adecuadamente. Según el National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), la afección ocurre más comúnmente después de pequeñas cirugías de resección intestinal realizadas para enfermedades como la enfermedad de Crohn, cánceres intestinales, traumatismo, obstrucción intestinal, isquemia y trastornos intestinales congénitos. La creciente incidencia de enfermedades inflamatorias intestinales, especialmente la enfermedad de Crohn, contribuye significativamente al aumento de las cirugías intestinales en todo el mundo. NIDDK también afirma que los pacientes con enfermedad severa de Crohn a menudo requieren reseecciones de intestino repetidas, lo que aumenta el riesgo a largo plazo de desarrollar SBS-IF.

Restricción clave / desafío: alto costo de SBS-Si el tratamiento

El alto costo del tratamiento SBS-IF sigue siendo una de las mayores restricciones para el mercado de tratamiento Europe Type 1 SBS-IF. Los pacientes con síndrome del intestino corto con insuficiencia intestinal a menudo requieren nutrición parenteral permanente, monitoreo hospitalario frecuente, rehabilitación intestinal especializada y terapias biológicas avanzadas como teduglutida. Según la información de tratamiento de EE.UU. Food and Drug Administration y Takeda, las terapias GLP-2 como GATTEX pueden costar casi USD 400.000–USD 500.000 al año por paciente en los Estados Unidos, haciendo que el tratamiento sea financieramente difícil para muchas familias y sistemas de salud. Además de los costos de los fármacos, los pacientes con SBS-IF a menudo necesitan atención central de catéter venoso, suplementos nutricionales, pruebas regulares de sangre y reincidencias hospitalarias debido a infecciones o complicaciones de deshidratación. Estos gastos médicos a largo plazo suponen una carga importante tanto para los pacientes como para los proveedores de seguros, especialmente en los países donde la cobertura de reembolso por enfermedades raras sigue siendo limitada.

Oportunidad del mercado clave: Ampliación de terapias analógicas avanzadas y GLP-2.

El mercado de tratamiento Europa Tipo 1 SBS-IF presenta importantes oportunidades de crecimiento impulsadas por avances continuos en enfoques de manejo terapéutico y nutricional. Aumentar la adopción de nuevas tecnologías biológicas, en particular las terapias analógicas GLP-2, está creando nuevas vías para mejorar la adaptación intestinal y reducir la dependencia de la nutrición parenteral. El enfoque cada vez mayor en los planes de nutrición personalizados y la atención multidisciplinaria es mejorar los resultados de los pacientes y ampliar la accesibilidad al tratamiento. Las economías emergentes ofrecen un potencial considerable debido a la mejora de la infraestructura sanitaria, una mayor conciencia de los trastornos gastrointestinales raros y el aumento del gasto sanitario. Además, la investigación en curso en medicina regenerativa, terapias basadas en células madre e ingeniería de tejido intestinal puede transformar futuros paradigmas de tratamiento. También se espera que la ampliación de los modelos de atención en el hogar y las soluciones de control remoto mejoren la gestión de enfermedades a largo plazo y la calidad de vida de los pacientes

Europa Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

El mercado se segmenta sobre la base de la modalidad de tratamiento, atribución al mercado, fase de gestión de enfermedades, tipo de paciente, vía de administración, tipo intravenoso, usuario final y canal de distribución.

Por Modalidad de Tratamiento

Sobre la base de la modalidad de tratamiento, el SBS-IF de Europa tipo 1 (Síndrome de Short Bowel con falla intestinal) El mercado de tratamiento se segmenta en terapia de apoyo nutricional, terapia farmacológica, tratamiento intervencional quirúrgico y terapias avanzadas emergentes. El segmento de la terapia de apoyo nutricional dominó la mayor cuota de ingresos del mercado de 41,87% en 2025, impulsada por la creciente dependencia de la nutrición parenteral y enteral para la gestión SBS-IF a largo plazo en hospitales y entornos de salud en el hogar. El aumento de la adopción de los programas de nutrición parenteral (HPN), los avances en las formulaciones clínicas de nutrición y el creciente enfoque en la mejora de la calidad de vida del paciente continúan apoyando el crecimiento del segmento. La creciente prevalencia de cirugías gastrointestinales y trastornos intestinales crónicas acelera aún más la demanda de terapias de rehabilitación nutricional. La mejora del apoyo a los reembolsos y el aumento de la conciencia respecto de la gestión crónica de las fallas intestinales también contribuyen a una mayor adopción de segmentos en toda Europa.

Se prevé que el segmento de terapias avanzadas emergentes sea testigo de la CAGR más rápida del 7,5% entre 2026 y 2033, alimentada por la creciente adopción de biológicas, terapias analógicas GLP-2 y enfoques innovadores de rehabilitación intestinal. Aumentar las actividades de investigación centradas en enfermedades gastrointestinales raras y aumentar las inversiones en desarrollo avanzado del tratamiento SBS-IF están expandiendo el paisaje terapéutico. Las empresas farmacéuticas se centran cada vez más en la medicina de precisión y terapias orientadas para reducir la dependencia de la nutrición parenteral y mejorar la función intestinal. Los marcos regulatorios de apoyo, la expansión de ensayos clínicos y los avances en soluciones de tratamiento personalizadas contribuyen aún más al rápido crecimiento del segmento en el mercado de tratamiento del tipo SBS-IF de Europa.

By Market Attribution

Sobre la base de la atribución del mercado, la Europa Tipo 1 SBS-IF (Síndrome de Short Bowel con falla intestinal) El mercado de tratamiento se segmenta en el mercado central SBS-IF, mercado atribuible SBS-IF y mercado adyacente / no específico. El segmento central del mercado SBS-IF dominó la mayor cuota de ingresos del mercado de 56.61% en 2025, impulsada por el creciente diagnóstico de casos de insuficiencia intestinal que requieren apoyo nutricional especializado y gestión clínica a largo plazo. La creciente adopción de terapias de nutrición parenteral, el aumento de la conciencia sobre los trastornos intestinales crónicos y la ampliación del acceso a centros de tratamiento gastrointestinales especializados continúan apoyando el crecimiento del segmento. El aumento del gasto sanitario en enfermedades gastrointestinales raras y los avances en los programas de rehabilitación nutricional están acelerando aún más la demanda del mercado. Las políticas de reembolso mejoradas y la creciente integración de las soluciones de atención de la salud en el hogar también contribuyen a una fuerte adopción de segmentos en toda Europa.

Se prevé que el segmento de mercado atribuible SBS-IF sea testigo de la CAGR más rápida del 7,4% de 2026 a 2033, alimentada por el creciente reconocimiento de complicaciones relacionadas con SBS-IF y la creciente necesidad de intervenciones terapéuticas de apoyo. La creciente prevalencia de cirugías gastrointestinales, resecciones intestinales y trastornos digestivos crónicos está impulsando la demanda de soluciones de tratamiento atribuibles y programas de atención nutricional asociados. Los proveedores de atención médica se centran cada vez más en la gestión temprana de las enfermedades y en enfoques multidisciplinarios de tratamiento para mejorar los resultados de los pacientes. Los avances continuos en terapias biológicas, apoyo nutricional clínico y tecnologías de monitoreo de pacientes están contribuyendo aún más a la expansión de segmentos. Se espera que el aumento de las inversiones en la infraestructura de tratamiento de enfermedades raras y las iniciativas gubernamentales de apoyo lleven a un crecimiento rápido en todo el mercado europeo de tratamiento tipo 1 SBS-IF.

Por fase de gestión de enfermedades

Sobre la base de la fase de gestión de enfermedades, el mercado de tratamiento europeo tipo 1 SBS-IF (síndrome del intestino delgado con falla intestinal) se segmenta en fase aguda (Tipo 1 SBS-IF), fase de adaptación y fase de recuperación. El segmento de fase aguda (Tipo 1 SBS-IF) dominó la mayor cuota de ingresos del mercado de 48,57% en 2025, impulsado por el creciente número de pacientes que requieren intervención nutricional inmediata y manejo clínico intensivo tras cirugías intestinales y complicaciones gastrointestinales graves. El aumento de la dependencia del apoyo a la nutrición parenteral, el aumento de las tasas de hospitalización y la creciente demanda de atención gastrointestinal especializada siguen apoyando el crecimiento de los segmentos. Los avances en programas intensivos de terapia nutricional y mejores tecnologías de monitoreo están mejorando aún más los resultados del tratamiento. El aumento de la conciencia sobre el diagnóstico y la gestión tempranos de SBS-IF también contribuye a una fuerte adopción de segmentos en toda Europa.

Se prevé que la fase de adaptación sea testigo de la CAGR más rápida del 7,4% de 2026 a 2033, impulsada por el creciente enfoque en las estrategias de rehabilitación intestinal y optimización nutricional a largo plazo. Aumentar la adopción de terapias biológicas, programas de nutrición personalizados y enfoques avanzados de rehabilitación está apoyando una mejor adaptación intestinal y una menor dependencia de la nutrición parenteral. Los proveedores de atención médica están haciendo cada vez más hincapié en los modelos multidisciplinarios de tratamiento para mejorar la recuperación de pacientes y la calidad de vida. Los avances continuos en las formulaciones clínicas de nutrición y soluciones de gestión de la salud en el hogar contribuyen aún más a la expansión de segmentos. Se espera que el aumento de las inversiones en infraestructura de rehabilitación gastrointestinal y las innovaciones de tratamiento de apoyo impulsen un rápido crecimiento en el mercado de tratamiento europeo tipo 1 SBS-IF.

Por tipo de paciente

Sobre la base del tipo de paciente, el mercado de tratamiento europeo SBS-IF (síndrome del intestino delgado con falla intestinal) se segmenta en adulto y pediatría. El segmento adulto dominó la mayor cuota de ingresos del mercado de 71,35% en 2025, impulsada por la creciente prevalencia de trastornos gastrointestinales, resección intestinal y complicaciones digestivas crónicas entre la población adulta. Aumentar la dependencia de las terapias de nutrición parenteral a largo plazo, aumentar las tasas de hospitalización y la adopción creciente de programas de apoyo nutricional a la salud doméstica continúan apoyando el crecimiento del segmento. Los avances en las formulaciones nutricionales y los enfoques de atención gastrointestinales integrados están mejorando aún más los resultados del tratamiento. El aumento de la conciencia sobre la gestión crónica de las fallas intestinales y los marcos de reembolso de apoyo también contribuyen a una fuerte adopción de segmentos en toda Europa.

Se prevé que el segmento pediátrico sea testigo de la CAGR más rápida del 7,3% del 2026 al 2033, alimentada por la creciente incidencia de trastornos intestinales congénitos, complicaciones gastrointestinales neonatales y casos de insuficiencia intestinal pediátrica. Aumentar el enfoque en terapias especializadas de apoyo nutricional pediátrico y programas avanzados de rehabilitación intestinal está impulsando la expansión del segmento. Los proveedores de atención médica están adoptando cada vez más estrategias de tratamiento personalizadas y modelos multidisciplinarios de atención para mejorar los resultados de los pacientes pediátricos a largo plazo. Los avances continuos en las formulaciones de nutrición parenteral pediátrica y las soluciones de asistencia a domicilio contribuyen aún más al crecimiento del mercado. Se espera que el aumento de las inversiones en infraestructuras de tratamiento gastrointestinales pediátricas y el aumento de la conciencia acerca de las estrategias de intervención temprana aceleren la demanda de segmentos en todo el mercado europeo de tratamiento SBS-IF.

Por Ruta de Administración

Sobre la base de la vía de administración, la Europa Tipo 1 SBS-IF (Short Bowel Síndrome con falla intestinal) El mercado de tratamiento se segmenta en intravenosa, subcutánea, oral y enteral. El segmento intravenoso dominaba la mayor cuota de ingresos del mercado del 49,60% en 2025, impulsada por la creciente dependencia de las terapias de nutrición parenteral para la gestión inmediata y a largo plazo de SBS-IF. La administración intravenosa sigue siendo esencial para los pacientes con graves limitaciones de absorción intestinal y deficiencias nutricionales agudas. El aumento de la adopción de programas de nutrición parenteral (HPN), los avances en las tecnologías de la infusión y la creciente disponibilidad de formulaciones nutricionales especializadas continúan apoyando el crecimiento del segmento. El aumento de las tasas de hospitalización relacionadas con los trastornos gastrointestinales y los marcos de reembolso de apoyo están contribuyendo aún más a una fuerte adopción de segmentos en toda Europa.

Se prevé que el segmento subcutáneo será testigo de la CAGR más rápida del 7,4% de 2026 a 2033, alimentada por la creciente adopción de terapias biológicas y opciones avanzadas de tratamiento inyectable para la gestión SBS-IF. Aumentar la preferencia por métodos de entrega de drogas mínimamente invasivos, mejorar la comodidad de los pacientes y reducir la dependencia hospitalaria están impulsando la expansión del segmento. Los proveedores de atención de la salud utilizan cada vez más la administración subcutánea para terapias específicas y enfoques de gestión de enfermedades a largo plazo. Los avances continuos en las formulaciones biológicas, los dispositivos de autoadministración y los programas de tratamiento de la atención en el hogar contribuyen aún más al crecimiento del mercado. Se espera que el aumento de las inversiones en terapias gastrointestinales innovadoras y el aumento de la conciencia sobre soluciones de tratamiento centradas en el paciente aceleren la demanda de segmentos en todo el mercado europeo de tratamiento SBS-IF.

Por Usuario final

Sobre la base del usuario final, el mercado de tratamiento europeo tipo 1 SBS-IF (Síndrome del tazón corto con falla intestinal) se segmenta en hospitales (cuidado agudo), atención en casa (programas HPN), configuración de UCI, centros especiales de GI y hospitales de especialidades pediátricas. El segmento de hospitales (cuidado agudo) dominó la mayor parte de ingresos del mercado del 38,89% en 2025, impulsada por las crecientes tasas de hospitalización asociadas con insuficiencia intestinal, cirugías gastrointestinales y graves deficiencias nutricionales. Los hospitales siguen siendo la configuración primaria de tratamiento para el apoyo nutricional intensivo, la gestión aguda del SBS-IF y la atención gastrointestinal multidisciplinar. El aumento de la adopción de terapias de nutrición parenteral avanzadas, el aumento de la disponibilidad de equipos de atención especializada y la creciente inversión en programas de rehabilitación nutricional basados en hospitales siguen apoyando el crecimiento del segmento. Las estructuras de reembolso de apoyo y la mejora de la infraestructura clínica contribuyen aún más a una fuerte adopción de segmentos en toda Europa.

Se prevé que el segmento de atención a domicilio (programas de HPN) sea testigo de la CAGR más rápida del 7,7% de 2026 a 2033, alimentada por la creciente adopción de soluciones de nutrición parenteral para la gestión SBS-IF a largo plazo. Aumentar la preferencia por los enfoques de tratamiento basados en el hogar, mejorar la comodidad de los pacientes y reducir los costos de hospitalización están impulsando la expansión del segmento. Los proveedores de atención de salud están enfatizando cada vez más los programas de atención de salud para mejorar la calidad de vida y los resultados de gestión nutricional a largo plazo. Los avances continuos en sistemas de infusión portátiles, tecnologías de monitoreo remoto de pacientes y terapias nutricionales personalizadas están contribuyendo aún más al crecimiento del mercado. Se espera que el aumento de la conciencia sobre la gestión crónica de fallas intestinales y la ampliación de la infraestructura de atención de la salud en el hogar aceleren la demanda de segmentos en todo el mercado europeo de tratamiento SBS-IF.

Por canal de distribución

Sobre la base del canal de distribución, la Europa Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) El mercado de tratamiento se segmenta en farmacia hospitalaria, farmacia especializada, farmacia minorista y farmacia en línea. El segmento de farmacia hospitalaria dominó la mayor cuota de ingresos del mercado de 46.01% en 2025, impulsada por las crecientes tasas de hospitalización asociadas con el fracaso intestinal y la creciente administración de terapias de nutrición parenteral en entornos de atención aguda. Las farmacias hospitalarias siguen siendo los canales de distribución primaria para formulaciones nutricionales especializadas, terapias biológicas y productos intensivos de tratamiento SBS-IF. La creciente disponibilidad de programas multidisciplinarios de atención gastrointestinal y la creciente demanda de soluciones de tratamiento supervisadas clínicamente continúan apoyando el crecimiento del segmento. Los marcos de reembolso de apoyo y la ampliación de la infraestructura hospitalaria contribuyen aún más a una fuerte adopción de segmentos en toda Europa.

Se prevé que el segmento de farmacias especializadas sea testigo de la CAGR más rápida del 7,5% entre 2026 y 2033, alimentada por la creciente demanda de terapias biológicas avanzadas, formulaciones nutricionales personalizadas y soluciones de tratamiento SBS-IF a largo plazo. La creciente preferencia por los servicios especializados de apoyo farmacéutico y el mejor acceso a los productos de tratamiento de enfermedades raras están impulsando la expansión de segmentos. Los proveedores de atención de salud están colaborando cada vez más con las farmacias especializadas para garantizar el seguimiento continuo de pacientes, la gestión de terapia y el apoyo al tratamiento basado en el hogar. Los avances continuos en las redes de distribución de drogas especializadas y los programas de asistencia a los pacientes contribuyen aún más al crecimiento del mercado. Se espera que el aumento de la conciencia sobre la gestión crónica de fallas intestinales y la adopción creciente de enfoques de tratamiento centrados en el paciente aceleren la demanda de segmentos en todo el mercado europeo de tratamiento SBS-IF.

Europa Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Alemania dominó el mercado de tratamiento Tipo 1 SBS-IF y representó la mayor cuota de ingresos del 19,90% en 2025, respaldada por infraestructuras sanitarias avanzadas, marcos de reembolso favorables y la fuerte presencia de centros especializados de rehabilitación intestinal. La región se beneficia de una alta conciencia y un diagnóstico temprano del síndrome de intestino corto, una adopción generalizada de nutrición parenteral y terapias farmacológicas avanzadas, e importantes inversiones en investigación de enfermedades raras. Además, la disponibilidad de tratamientos biológicos innovadores, la actividad de ensayo clínico robusta y el firme apoyo reglamentario para los medicamentos huérfanos han contribuido al crecimiento del mercado. El aumento de la atención en la mejora de los resultados de los pacientes, la reducción de las complicaciones a largo plazo asociadas con el fracaso intestinal, y la ampliación del acceso a programas de atención multidisciplinar sigue reforzando la posición líder en América del Norte en el mercado de tratamiento del tipo SBS-IF de Europa.

U.K. Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

El mercado de tratamiento U.K. Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) cuenta con el apoyo de una infraestructura sanitaria bien desarrollada, la adopción creciente de terapias especializadas de apoyo nutricional y la ampliación del acceso a servicios multidisciplinarios de rehabilitación intestinal. El aumento de la conciencia de los trastornos gastrointestinales raros, las directrices clínicas favorables y los avances continuos en terapias biológicas y de medicamentos huérfanos contribuyen a mejorar los resultados de los pacientes y el crecimiento sostenido del mercado en todo el país.

Francia Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

El mercado de tratamiento Francia Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) está presenciando un crecimiento constante, apoyado por un fuerte sistema de salud pública, concienciando cada vez más de los trastornos gastrointestinales raros y ampliando el acceso a programas especializados de rehabilitación intestinal. La creciente adopción de la nutrición parenteral, las políticas favorables de medicamentos huérfanos y las iniciativas de investigación clínica en curso están mejorando la disponibilidad de tratamiento y mejorando los resultados de los pacientes en todo el país.

Italia Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

El mercado de tratamiento de Italia Tipo 1 SBS-IF (Síndrome de Bowel corto con falla intestinal) se está expandiendo debido al creciente reconocimiento de los trastornos de insuficiencia intestinal, mejorando el acceso a terapias de apoyo nutricional especializadas y la presencia de centros de gastroenterología dedicados. El aumento de la adopción de la nutrición parenteral en el hogar, las políticas de salud de apoyo y los avances en la gestión de enfermedades raras contribuyen al crecimiento del mercado y a la mejora de la atención de los pacientes.

España Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

El mercado de tratamiento del SBS-IF (Short Bowel Syndrome with Intestinal Failure) está creciendo constantemente, impulsado por el aumento del gasto sanitario, mayor conciencia de las enfermedades gastrointestinales raras y la ampliación de la disponibilidad de servicios especializados de rehabilitación intestinal. Aumentar la utilización de terapias nutricionales avanzadas, mejorar el acceso a tratamientos innovadores y continuar las actividades de investigación están apoyando una mejor gestión de las enfermedades y el desarrollo del mercado en todo el país.

Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

El tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Tratamiento La industria del mercado está dirigida principalmente por empresas bien establecidas, incluyendo:

Nestle Health Science (Suiza)

Stanford Health Care (Estados Unidos)
HOSPIRA (Ahora parte de Pfizer) (Estados Unidos)
Aurora Health Care (U.S.)
Takeda Pharmaceutical Company Limited (Japón)
Fresenius Kabi AG (Alemania)
Grifols (España)
Abbott Laboratories (U.S.)
Shandong Qidu Pharmaceutical Co., Ltd. (China)
Ferring Pharmaceuticals (Suiza)
UF Health (Estados Unidos)
Baxter International INC (U.S.)
VectivBio AG (Suiza)
Hikma Pharmaceuticals PLC (Reino Unido)
NUTRICIA (DANONE) (Países Bajos)
Amsino International, Inc. (U.S.)
Braun Melsungen AG (Alemania)
ContinuumRx (U.S.)
JEDUX PARENTERAL PRIVATE LIMITED (India)
Beverly Hills Digestive Care (Estados Unidos)
Elección de la Nutrición Parenteral LLC (U.S.)
Integrated Care Systems (U.S.)
Camvitaa (India)
Eclipse Regenesis (U.S.)
LABORATOIRE DIELEN (Francia)
Vision Parenteral Pvt. Ltd. (India)
Aculife Healthcare (India)
Nutrego (Polonia)
Pharmko, Inc. (U.S.)
Infusion Solutions (U.S.)
UF Health (Estados Unidos)
Integrated Care Systems (U.S.)
Elección de la Nutrición Parenteral LLC (U.S.)
ContinuumRx (U.S.)
NUTRICIA NORTH AMERICA (Estados Unidos)
Terapéutica Napo (U.S.)
a Moog company (Estados Unidos)
ICU Medical, Inc. (Estados Unidos)
Eclipse Regenesis (U.S.)
Puerto Life Sciences Pvt. Ltd (India)

Bausch Health Companies (Canadá)

Últimos desarrollos en Europa Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal) Mercado de Tratamiento

En enero de 2026, Fresenius Kabi ha introducido una nueva forma de dosificación de su ustekinumab biosimilar (Otulfi), que ofrece un vial de dosis única de 45 mg/0,5 mL. Esta adición amplía el rango de presentación disponible de Otulfi, que es un biosimilar a Stelara de Janssen (ustekinumab). Con esta actualización, Fresenius Kabi proporciona ahora múltiples formas de dosis y fortalezas del producto de referencia, mejorando la flexibilidad para los médicos y opciones de tratamiento para los pacientes. Esto fortalece la cartera biosimilar de Fresenius Kabi mejorando la flexibilidad del producto.
En marzo de 2025, Baxter International ha introducido el IV Verify Line Labeling System, una solución automatizada diseñada para reemplazar etiquetas IV manuscritas con etiquetado estandarizado y basado en códigos de barras en hospitales. El sistema ayuda a los clínicos a imprimir etiquetas adhesivas claras y codificadas por colores para el tubo IV, mejorando la precisión y reduciendo errores de medicamentos en la parte posterior. Fortalece la posición de Baxter en la tecnología de infusión hospitalaria.e
En febrero de 2026, Nestlé Health Science anunció la inclusión de sus productos nutricionales en un marco de reembolso excepcional dentro del sistema de salud pública de Portugal, permitiendo que los productos elegibles sean cubiertos parcialmente o totalmente por el Servicio Nacional de Salud. Esta decisión regulatoria refuerza el acceso de los pacientes a soluciones de nutrición clínica y apoya la integración de la nutrición médica en vías formales de reembolso de salud. Esto beneficiará a la empresa mejorando la accesibilidad de los productos, ampliando la demanda basada en recetas y reforzando su posición dentro del mercado clínico de nutrición reembolsado.

SKU-76248

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

Click on image to enlarge

Panel de análisis de datos interactivo
Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
Acceso de analista de investigación para personalización y consultas
Análisis de la competencia con panel interactivo
Últimas noticias, actualizaciones y análisis de tendencias
Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia

Solicitud de demostración

Tabla de contenido

1 INTRODUCCIÓN

1.1 OBJETIVOS DEL ESTUDIO

1.2 DEFINICIÓN DEL MERCADO

1.3 Vista general de EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITACIONES

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 ÁMBIÉN GEOGRÁFICO

2.3 AÑOS ESTUDIOS PARA EL ESTUDIO

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 ENTREVISTAS PRIMARÍAS CON LEADRES DE OPINION KEY

2.6 GRID DE POSICIÓN DEL MERCADO

2.7 VENDOR SHARE ANALISIS

2.8 MULTIVARIATE MODELING

2.9 CURVE DE TIPO DE PRODUCTOS

2.1 MARKET APPLICATION GRID

2.11 FUERZAS SEGUNDARIAS

2.12 ASUNTOS

RESUMEN EJECUTIVO

4 fotos INSIGHTS

4.1 ANÁLISIS PESTEL

4.1.1 INTRODUCCIÓN

4.1.2 ANÁLISIS POLÍTICO

4.1.3 ANÁLISIS ECONÓMICO

4.1.4 ANÁLISIS SOCIAL

4.1.5 ANÁLISIS TECNOLOGICO

4.1.6 ANÁLISIS AMBIENTE

4.1.7 ANÁLISIS JURÍDICO

4.1.8 CONCLUSIÓN

4.2 FIVE FORCES DE PORTER

4.2.1 INTRODUCCIÓN

4.2.2 INTENSITY OF COMPETITIVE RIVALRY (HIGH)

4.2.3 POWER BARGAINING POWER OF BUYERS – ALTO

4.2.4 Tres de los nuevos territorios - MODERATE

4.2.5 THREAT OF SUBSTITUTE PRODUCTS – MODERATE

4.2.6 BARGAINING POWER OF SUPPLIERS – MODERATE

4.2.7

4.3 QUADRANT DE EVALUACIÓN DE EMPRESAS

4.4 METODOLOGÍA DEL FONDO PACTO (MODEL DE MANDATORIA)

4.4.1 Un FONDO PACIENTE DE BOTTOM-UP será CONSTRUCIDO

4.4.1.1 POBLACIÓN TOTAL DE SBS

4.4.1.2 POBLACIÓN SBS-IF

4.4.1.3 DIAGNOSED SBS-IF PATIENTS

4.4.1.4 PACIENTES TREATED SBS-IF

4.4.1.5 POOLAS PACIENTES THERAPY-SPECIFIC

4.4.1.6 ESTE ENSURES PATIENT NUMBERS are DIRECTLY ESTIMATED, NO INFERREDED from MARKET SIZE

4.4.1.7 EUROPA PATIENT FUNNEL SEGMENTATION

4.4.1.8 POBLACIÓN TOTAL DE SBS

4.4.1.9 SBS ADULT

4.4.1.10 PEDIATRIC SBS

4.4.1.11 POBLACIÓN SBS-IF

4.4.1.12 TYPE 1 SBS-IF (ACUTE)

4.4.1.13 TYPE 2 SBS-IF (PROLONGED ACUTE)

4.4.1.14 TYPE 3 SBS-IF (CHRONIC)

4.4.1.15 POBLACIÓN DIAGNOSADA

4.4.1.16 DIAGNOSED – HOSPITAL-BASED

4.4.1.17 DIAGNOSED – OUTPATIENT

4.4.1.18 UNDIAGNOSED / MISCLASSIFIED

4.4.1.19 POBLACIÓN PACIENTE TREATED

4.4.1.20 PACIENTES TREATEDES

4.4.1.21

4.4.2 TREATMENT-SPECIFIC PATIENT SEGMENTATION (CRITICAL)

4.4.2.1 POPULACIÓN PACIENTE PN-DEPENDIENTO (SEGMENTO DE CORE)

4.4.2.2 FULLY PN-DEPENDENT

4.4.2.3 PARTIALLY PN-DEPENDENT

4.4.2.4 UCI PN-DEPENDENT (TYPE 1 ACUTE)

4.4.2.5 HOME PN-DEPENDENT

4.4.2.6 GLP-2 ANALOGUE TREATED PATIENTS

4.4.2.7 INCLUYEN LOS PACIENTES RECIBIDAS

4.4.2.8 PIPELINE THERAPIES (E.G., APRAGLUTIDE)

4.4.2.9

GLP-2

4.4.2.11 PN-WEANING PATIENTS

4.4.2.12 PEDIATRIC VS ADULT

4.4.2.13 PHARMACOTHERAPY PATIENTS (ATTRIBUTABLE)

4.4.2.14 USUARIOS ANTI-DIARRHEAL

4.4.2.15

4.4.2.16 ANTIBIOTIC (SIBO) PACIENTES

4.4.2.17 MICRONUTRIENT-DEPENDENT PATIENTS

4.4.2.18 PACIENTES SURGICOS Y TRANSPLANTES

4.4.2.19 PROCEDIMIENTOS DE LENGTHENAL

4.4.2.20 PACIENTES TRANSPLANTES

4.4.2.21 SURVIVORS POST-TRANSPLANT

4.4.3 SEGMENTACIÓN PACIENTE POR DEPENDENCY STATUS (HIGHLY IMPORTANT)

POPULACIÓN PN-DEPENDIEN

4.4.3.2 SEGUIMIENTO DE LA REVENCIÓN DE LOS PAÍSES

4.4.3.3 POPULACIÓN DE PNBANING

4.4.3.4 RESPONDERS GLP-2

POPULACIÓN PN-INDEPENDENT

4.4.3.6 MAINTAINED ON ORAL/ENTERAL THERAPY

4.4.4 SEGMENTACIÓN PACIENTE POR FASE DISEÑO (TYPE 1 FOCUS)

4.4.4.1 ACUTE PHASE (TYPE 1 SBS-IF)

4.4.4.2 ICU-MANAGED PATIENTS

4.4.4.3 HIGH PN UTILIZATION

4.4.4.4 FASE DE ADAPTACIÓN

4.4.4.5 TRANSICIÓN A LA NUTRICIÓN ENTERAL

4.4.4.6 INITIATION OF GLP-2 THERAPY

4.4.4.7 HABILIZACIÓN / ESTABILIZACIÓN

4.4.4.8 REDUCED PN DEPENDENCY

4.4.4.9 MANTENIMIENTO DE LOS TERMINOS

4.4.4.10 SEGMENTACIÓN PACIENTE POR CARE

4.4.4.11 PACIENTES HOSPITAL-BASED

4.4.4.12 UCID

4.4.4.13 WARDS SURGICAS

4.4.4.14 PACIENTES DE CARE

4.4.4.15 HOME PARENTERAL NUTRITION (HPN)

4.4.16 CENTROS ESPECIALES

4.4.4.17 CENTROS INTESTINALES DE REHABILITACIÓN

4.4.5 SEGMENTACIÓN PACIENTE POR LOS DEMOGRAFÍAS

4.4.5.1 GRUPO DE AGE

4.4.5.2 NEONACIONES

4.4.5.3 PEDIATRIC

4.4.5.4

4.4.5.5 GERIATRIC

4.4.5.6 GENDER

4.4.5.7

4.4.5.8 FEMALE

4.4.6 SEGMENTACIÓN PACIENTE POR ETIOLOGÍA

4.4.6.1 ETIOLOGÍA ADULT

4.4.6.2 DISEÑO DE CROHN

4.4.6.3 MESENTERIC ISCHEMIA

4.4.6.4 Respuestas SURGICAS

4.4.6.5 REALIZADO DE LAS NACIONES UNIDAS

4.4.6.6 ETIOLOGÍA PEDIATRIC

4.4.6.7 NECROTIZING ENTEROCOLITIS (NEC)

4.4.6.8 DEFECTOS CONGENIALES (ATRESIA, GASTROSCHISIS)

4.4.7 DISTRIBUCIÓN PACIENTE GEOGRÁFICO

4.4.7.1 NORTH AMERICA

4.4.7.2 U.S.

4.4.7.3 CANADA

4.4.7.4 EUROPA

4.4.7.5 ALEMANIA

4.4.7.6

4.4.7.7 Reino Unido

4.4.7.8

4.4.7.9 ESPAÑA

4.4.7.10 ASIA-PAIFIC

4.4.7.11 JAPÓN

4.4.7.12 CHINA

4.4.7.13 INDIA

4.4.8 TREATMENT PENETRATION " UTILIZATION RATES

4.4.8.1 PN PENETRATION RATE

4.4.8.2 % DE PACIENTES SBS-IF EN PN

4.4.8.3 GLP-2

4.4.8.4 % DE LOS PACIENTES ELIGIBLES GLP-2

4.4.8.5 Perfeccionamiento de la Terapia

4.4.8.6 ANTI-DIARRHEAL USAGE RATE

4.4.8.7 PPI USAGE RATE

4.4.8.8 Modificación de los GASTOS PATIENT-LEVEL

4.4.8.9 Gastos anuales

4.4.8.10 PN COST (HOSPITAL VS HOME)

4.4.8.11 GLP-2 THERAPY COST

4.4.8.12 GASTOS DE ARAPACIDAD

4.4.9 COST BY PATIENT TYPE

4.4.9.1 PN-DEPENDENT

4.4.9.2 GLP-2

4.4.9.3

4.4.9.4 DELIVERABLES DELPUT (EXCEL – CLIENT CRITICAL)

4.4.9.5 PACIENTES TOTAL SBS-IF (Por país)

4.4.9.6 VS DIAGNOSED TREATED PATIENTS

4.4.9.7 PN-DEPENDENT PATIENTS

4.4.9.8 GLP-2 TREATED PATIENTS

4.4.9.

4.4.9.10 AVERAGE ANNUAL COST PER THERAPY

4.5 INSIGHTS INDUSTRY

4.5.1 INTRODUCCIÓN

4.5.2 Examen general de la estructura interna

4.5.3 MICRO Y FACTORES ECONÓMICOS MACRO

4.5.4 PENETRATION AND GROWTH PROSPECT MAPPING

4.5.5 ESTRATEGIAS PRINCIPALES

4.5.6 INTERVIEWS with SPECIALISTS

4.5.7 ANÁLISIS Y RECOMENDACIÓN

4.5.8 CONCLUSIÓN

4.6 LA DISRUPCIÓN DE LA GUERRA DE LA GUERRA DE LOS CHAINS PHARMACEUTICAS SUPPLY, GEOGRAPHIC FOOTPRINTs, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES

INTRODUCCIÓN

4.6.2 RESULTIVAMENTE CHAIN

4.6.2.1 DIVERSIFICACIÓN DE LOS SUPLEMENTOS INGRESOS Y PN/DRUG

4.6.2.2 ESTABLECIMIENTO DE LOS HUBES DE PRODUCCIÓN REGIONAL

STRATEGIC STOCKPILING OF CRITICAL PN BAGS, GLP-2 ANALOGUES, AND MEDICAL DEVICES

4.6.2.4 DESARROLLO DE LAS LOGISTICAS ALTERNATIVAS Y LOS CHAINES COLOS

4.6.2.5 CENTROS ESTRATEGICOS CON CDMOS LEADING (E.G., CATALENT, LONZA)

4.6.2.6 EXPANSION OF MANUFACTURING, FILL-FINISH, AND PACKAGING CAPABILITIES FOR PN & GLP-2

4.6.3 ENERGÍA " MANUFACTURING OPERATIONAL COST RISK

4.6.3.1 RISING ENERGY COSTS IN PARENTERAL NUTRITION ' DRUG FACILITIES

4.6.3.2 GASTOS INCREADOS PARA MATERIALES RAW, EMULSIONES LIPID, Y PHARMACEUTICAS

4.6.3.3 ESTRATEGIAS DE PROCURACIÓN DE LA ENERGÍA ENTRE LOS PN MANUFACTURERES

4.6.3.4 APROBACIÓN DE LAS TECNOLOGÍAS DE MANUFACTURACIÓN DE ENERGÍAS

4.6.3.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS SYSTEMS

4.6.3.6 INTEGRACIÓN DE LA ENERGÍA RENEWABLE EN LAS FACILIDADES DE MANUFACTURACIÓN

4.6.4 Observaciones de la FOOTPRINT GEOGRAPHIC

4.6.4.1 EXPANSION OF MANUFACTURING IN STABLE REGIONS

4.6.4.2 DIVERSIFICACIÓN DE PN/GLP-2 PRODUCTION SITES

4.6.4.3 RELOCACIÓN DE LA PRODUCCIÓN DE KEY INPUT/INTERMEDIATE

4.6.4.4 EXPANSION INTO EMERGING MARKETS with HIGH SBS-IF BURDEN

4.6.4.5 ESTABLECIMIENTO DE LOS HUBOS DE TRANSICIÓN Y DISTRIBUCIÓN REGIONALES

4.6.5 Plantilla SCENARIO " RISK MANAGEMENT

4.6.5.1 DESARROLLO DE PLANES DE CONTINGENCY SUPLEMENTE

4.6.5.2 ESTRATEGIAS DE PROCURACIÓN MULTI-SOURCE PARA PN/GLP-2

4.6.5.3 COLABORACIONES DE GOBIERNO Y SALUD

4.6.5.4 Redes de respuesta de la crisis para las terapias críticas

4.6.5.5 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS IN SBS-IF MARKET

4.6.6 CASH " FINANCIERA PROTECCIÓN

4.6.7 RESERVAS DE CAPITAL PARA LA EXPANSIÓN PN " BIOPHARMA

4.6.7.1 DIVERSIFICACIÓN DE LOS PORFOLIOS DE PRODUCTOS Y LAS ESFERAS REVENIDAS

4.6.7.2 INVESTMENTOS EN LA INFRASTRUCTURA DE LA PRODUCCIÓN DOMESTICA

4.6.7.3 INSTITUCIONES DE GOBIERNO Y PARTE PUBLIC-PRIVATE

4.6.7.4 LONG-TERM PROCUREMENT CONTRACTS with HEALTHCARE SYSTEMS

4.6.8 Protección de datos

4.6.8.1 MARCOS DE PROTECCIÓN DE DATOS PARA LOS DATOS CLINICOS Y REALES

4.6.8.2 PROTECCIÓN DE DATOS TRIALES CLINICOS, DATOS PACIENTES Y DESARROLLO DE DROGAS

4.6.8.3 SECURE CLOUD INFRASTRUCTURE FOR SBS-IF DATA MANAGEMENT

4.6.8.4 INTRODUCCIÓN DE LA TERCERA DETECCIÓN DE LA INVESTIGACIÓN Y LAS REDES DE PHARMA

4.6.8.5 CUMPLIMIENTO DE LAS REGULACIONES DE DATOS PHARMACEUTICAS " GXP

4.6.9 NUEVA BUSINESS AND EMERGING REVENUE OPPORTUNITIES " FUTURE OUTLOOK

4.6.10 Conclusión

4.7 EPIDEMIOLOGY

INTRODUCCIÓN

4.7.2 INCIDENCE OF TYPE 1 SBS-IF BY GENDER

4.7.3 TREATMENT RATE

4.7.4 MORTALITY RATE

4.7.5 TREATMENT ADHERENCE AND SWITCH MODEL

4.7.6 TREATMENTO DE TRATAMIENTO

4.7.7 Conclusión

4.8 DISTRIBUCIÓN DE PRODUCTOS Y PROYECTOS POR PHASE EUROPE TYPE 1 SBS-IF MARKET

4.9 DISTRIBUCIÓN DE LOS PROYECTOS POR APPROACH CIENTÍFICO Y FASE – EUROPA TYPE 1 SBS-IF MARKET

4.1 DISTRIBUCIÓN DE LOS PROYECTOS POR EL AREA Y LA PHASE THERAPEUTIC – EUROPE TYPE 1 SBS-IF MARKET

4.11 ANÁLISIS PIPELINA

INTRODUCCIÓN

4.11.2 TRIALS CLINICAL AND PHASE ANALYSIS

4.11.3 PIPELINA DE DROGAS

4.11.4 PHASE III CANDIDATES (E.G., APRAGLUTIDE)

4.11.5 PHASE II CANDIDATES (E.G., LONG-ACTING GLP-2)

4.11.6 FASE I CANDIDATES (EMERGING REGENERATIVE/CELLULAR)

4.11.7 OTHERS (PRE-CLINICAL, EN FORMULATION PIPELINE)

4.11.8 CONCLUSIÓN

4.12 ANÁLISIS PIPELINA

INTRODUCCIÓN

4.12.2 EMPRESA DE LA PHARMACEUTICA DE TAKEDA – LÍADERSHIP DE LA REGENERACIÓN INTESTINAL

4.12.3 BAXTER INTERNATIONAL – PARENTERAL NUTRITION AND INFUSION SYSTEM INNOVATION

4.12.4 FRESENIUS KABI AG – LA NUTRICIÓN CLINICA Y EL DESARROLLO DE LA THERAPY INJECTABLE

4.12.5 NESTLÉ HEALTH SCIENCE – MEDICAL NUTRITION AND GUT ADAPTATION RESEARCH

4.12.6 LABORATORES ABBOTT – INTEGRATED NUTRITION AND METABOLIC MONITORING SOLUTIONS

4.12.7

4.13 ANÁLISIS DE THERAPY MARKETED

INTRODUCCIÓN

4.13.2 DRUG/THERAPY

4.13.2.1 MARCO

4.13.2.2 Nombre de los GENERICES

4.13.3 CLASIFICACIÓN PHARMACOLOGICA

4.13.4 INDICACIÓN PRIMARIA

4.13.5 MARKET STATUS

4.13.6 Medios de acción

4.13.7

4.13.8 DISPONIBILIDAD

4.13.9 PACKAGING TYPE

4.13.10 ROUTE OF ADMINISTRATION

4.13.11 FRECUENCIA DE DOS

4.13.12 INSIGHT

4.13 Una visión general de las actividades de desarrollo de la sequía, las miles de carácter reglamentario, la seguridad y la administración, los datos sobre la exclusividad del mercado

4.13.14 FORECAST MARKET OUTLOOK

4.13.14.1 CROSS COMPETITION

4.13.14.2 THERAPEUTIC PORTFOLIO

4.13.14.3 CURRENT DEVELOPMENT SCENARIO

4.13.15

4.14 ANALISIS PIPELINA - EUROPA TYPE 1 MERCADO DE TRATAMIENTO SBS-IF

4.14.1 TRIALS CLINICAL AND PHASE ANALYSIS

4.14.2 PIPELINA DE DROGAS Y BIOTHERAPY

4.14.3 PHASE III CANDIDATES

4.14.4 PHASE II CANDIDATES

4.14.5 PHASE I CANDIDATES

4.14.6 OTHERS (PRE-CLINICAL AND RESEARCH STAGE)

4.15 R ' D ANALYSIS

ANÁLISIS COMPARATIVO

4.15.2 LANDSCAPE PARA EL DESARROLLO

4.15.3 INSIGHTS ON REGULATORY MILESTONES

4.15.4 Asistencia técnica

4.15.5 COLABORACIONES Y PARTICIPACIONES DE ASISTENCIA

5 HEALTHCARE TARIFFS IMPACT ANALYSIS

5.1 Examen general

5.2 ESTRUCTURAS DE TARIFF

5.2.1 EUROPA VS. REGIONAL TARIFF STRUCTURES

5.2.2 ESTADOS UNIDOS: MEDICARE/MEDICAID TARIFF POLICIES

5.2.3 ASIA-PACIFIC: GOVERNMENT TARIFFS ON IMPORTED PN/DRUG THERAPIES

5.2.4 MARKETS EMERGING: TARIFF CHALLENGES FOR NUTRITION " BIOLOGICS

5.2.5 MAJOR MARKET UPTAKE

5.3 TARIFAS PHARMACEUTICAS Y BARRIERS TRADE

5.3.1 IMPORT DUTIES ON PN KITS, GLP-2 VS. GENERICS

5.3.2 IMPACT ON AFFORDABILITY " ACCESS

5.3.3 ACUERDOS DE COMERCIO DE KEY AFECTANDO PRODUCTOS SBS-IF

5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS/PATIENTS

5.4.1 COST BURDEN ON HOSPITALS AND FACILITIES

5.4.2 EFECTO SOBRE LA AFFORDABILIDAD PACIENTE

5.4.3 HABITACIÓN EN EL TOURISMO MEDICAL PARA LAS ARMAS DE SBS-IF

5.5 ACUERDOS DE COMERCIO Y ACTIVIDADES DE SALUD

5.5.1 REGULACIONES DE LA OMC

5.5.2 EJECUCIÓN DE AGUAS COMERCIALES EN EL CAPÍTULO

5.5.3 FTAS IN REDUCING TARIFFS

5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

6 MARKET ACCESS

6.1 10 años de duración

6.2 Subsidios regionales

6.3 APROBACIONES NUEVAS DEL FDA ANUAL PARA LOS TRATAMIENTOS SBS-IF

6.4 MANUFACTURES, DISTRIBUTORS, AND DEALS

6.5 MAJOR MARKET UPTAKE

6.6 PRÁCTICAS DE TRATAMIENTO ACTUAL

6.7 IMPACT OF UPCOMING THERAPIES

7 MARCO REGULATORIO –

7.1 INTRODUCCIÓN

7.2 PROCESO DE APROBACIÓN REGULATORIA

7.3 EASE of REGULATORY APPROVAL

7.4 PATHWAYS DE APROBACIÓN REGULATORIA

7.5 LICENCIA Y REGISTRACIÓN

7.6 POST-MARKEILLANCE

7.7 Guías de buenas prácticas de manipulación

7.8 CONCLUSIÓN

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING SBS-IF PATIENT POPULATION

8.1.2 APROBACIÓN DE LA APROBACIÓN DE LAS ARMAS GLP-2

8.1.3 INCREASING GOVERNMENT " ORPHAN DRUG SUPPORT

8.2 RESTRAINTS

8.2.1 GASTOS DE SBS-IF

8.2.2 LIMITE.D AWARENESS & DELAYED DIAGNOSIS

8.3 OPORTUNIDADES

8.3.1 GESTIÓN DE LOS PACIENTES MULTIDISCIPLINARIOS

8.3.2 PROCESOS DE APROBACIÓN REGULATORIA ESTUDIANTE

8.4

8.4.1 AVANCES IN REGENERATIVE MEDICINE

8.4.2 EXPANSION OF HOME-BASED NUTRITIONAL CARE

9 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY

9.1 Examen general

9.2 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

9.2.1 NUTRITIONAL SUPPORT THERAPY

9.2.2 Terapia PHARMACOLOGICA

9.2.3 TREATMENTO SURGICO e INTERVENTIONAL

9.2.4 EMERGING " ADVANCED THERAPIES

9.3 EUROPE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.3.1 PARENTERAL NUTRITION (PN)

9.3.2 ENTERAL NUTRITION (EN)

9.3.3 PN COMPOSITION

9.4 EUROPE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.4.1 HOME PARENTERAL NUTRITION (HPN)

9.4.2 LA NUTRICIÓN PARENTERAL PERIPHERAL (PPN)

9.4.3 ADPIC PARENTERAL

9.5 EUROPA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.5.1 TPN HOSPITAL-BASED

9.5.2 PT PNB

9.6 EUROPA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

9.6.1 HPN ADULT

9.6.2 PEDIATRIC HPN

9.7 EUROPE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

9.7.1 HPN LONG-TERM

9.7.2 HPN SHORT-TERM

9.8 EUROPE ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.8.1 FEEDING ORAL

9.8.2 TUBE FEEDING

9.8.3 FORMULA TYPE

9.9 EUROPA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.9.1 NASOGASTRIC (NG)

9.9.2 PEG FEEDING

9.9.3 JEJUNOSTOMY FEEDING

9.1 EUROPE FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.10.1 POLYMERIC

9.10.2 ELEMENTAL

9.10.3 SEMI-ELEMENTAL

9.11 EUROPE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.11.1 MACRONUTRIENTS

9.11.2 ELECTROLYTES " FLUIDS

9.11.3 MICRONUTRIENTS

9.12 EUROPA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.12.1 AMINO ACIDS

9.12.2 EMULSIONES LIPID

9.12.3 DEXTROSE

9.13 EUROPA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.13.1 VITAMINS

9.13.2 ELEMENTOS DE TRABAJO

9.14 EUROPE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.14.1 NORTH AMERICA

9.14.2 EUROPA

9.14.3 ASIA-PACIFIC

9.14.4 ORIENTE MEDIO Y ÁFRICA

9.14.5 SOUTH AMERICA

9.15 EUROPE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.15.1 Terapia de ADAPTACIÓN HORMONAL

9.15.2 Terapia ANTI-DIARHEAL

9.15.3 ANTI-SECRETORY THERAPY

9.15.4 APLICACIÓN MICRONUTRIENTE

9.15.5 THERAPY ANTI-INFECTIVE

9.15.6 BILE ACID " ABSORPTION MODIFIERS

9.16 EUROPE HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.16.1 ANÁLOGO GLP-2

9.16.2 GROWTH HORMONE THERAPY

9.16.3 IGF-1 " ANALOGUES

9.17 EUROPE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.17.1

9.17.2 APRAGLUTIDE (LATE-STAGE)

9.17.3 ANALOGOS GLP-2 DE CUMPLIMIENTO

9.18 EUROPE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

9.18.1 HUMATROPE

9.18.2 NORDITROPIN

9.18.3 GENOTROPIN

9.19 EUROPE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.19.1 INCRELEX

9.19.2 OTROS

9.2 EUROPE ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.20.1 OPIOID-BASED

9.20.2 ORGANIZACIONES NO ORGANIZADAS

9.21 EUROPE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.21.1 LOPERAMIDE

9.21.2 CODEINA

9.22 EUROPE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.22.1 INHIBITORES DE PUMP PROTON

9.22.2 ANÁLOGOS SOMATOSTATALES

9.22.3 H2 RECEPTOR ANTAGONISTAS

9.23 EUROPE PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.23.1 OMEPRAZOLE

9.23.2 PANTOPRAZOLE

9.23.3 ESOMEPRAZOLE

9.23.4 OTROS

9.24 EUROPE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

9.24.1 OCTREOTIDE

9.24.2 OTROS

9.25 EUROPE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.25.1 FAMOTIDINE

9.25.2 OTROS

9.26 EUROPE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.26.1 VITAMINAS FAT-SOLUBLE (A, D, E, K)

9.26.2 ELECTROLYTES

9.26.3 VITAMIN B12

9.26.4 APLICACIÓN MINERAL

9.27 EUROPE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.27.1 ANTÍTICOS BROAD-SPECTRUM

9.27.2 THERAPY

9.28 EUROPE BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.28.1 BILE ACID SEQUESTRANTS

9.28.2 FAT ABSORPTION ENHANCERS

9.29 EUROPE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.29.1

9.29.2 COLESEVELAM

9.29.3 Otros

9.3 EUROPE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.30.1 NORTH AMERICA

9.30.2 EUROPA

9.30.3 ASIA-PACIFIC

9.30.4 ORIENTE MEDIO Y ÁFRICA

9.30.5 SOUTH AMERICA

9.31 EUROPE SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.31.1 PROCEDIMIENTOS DE LA LENGTHENAL

9.31.2 OSTOMÍA " RECONSTRUCCIÓN "

9.31.3 TRANSPLANTACIÓN INTESTINAL

9.32 EUROPE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.32.1

9.32.2 BIANCHI PROCEDURE

9.33 EUROPE OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.33.1

9.33.2 JEJUNOSTOMY

9.33.3 REVERSAL SURGERY

9.34 EUROPE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.34.1 CENTRO SMALL ISOLATED

9.34.2 LIVER + INTESTINE

9.34.3 TRANSPLANT MULTIVISCERAL

9.35 EUROPE SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.35.1 NORTH AMERICA

9.35.2 EUROPA

9.35.3 ASIA-PACIFIC

9.35.4 ORIENTE MEDIO Y ÁFRICA

9.35.5 SOUTH AMERICA

9.36 EUROPE EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.36.1 MEDICINA

9.36.2 Terapia de apoyo a la MICROBIOME

9.36.3 GENE THERAPY

9.37 EUROPE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.37.1

9.37.2 INTESTINA TISSUE-ENGINEERED

9.38 EUROPE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.38.1

9.38.2 FMT

9.39 EUROPE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.39.1 Inicio de la FUNCIÓN ABSORPTIVE

9.39.2 MUCOSAL GROWTH MODULATION

9.4 EUROPE EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

9.40.1 NORTH AMERICA

9.40.2 EUROPA

9.40.3 ASIA-PACIFIC

9.40,4 MIDDLE EAST AND AFRICA

9.40.5 SOUTH AMERICA

10 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION

10.1 Examen general

10.2 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

10.2.1 CORE SBS-IF MARKET

10.2.2 SBS-IF

10.2.3 ADJACENT / NON-SPECIFIC MARKET

10.3 EUROPE CORE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.3.1 PARENTERAL NUTRITION

10.3.2 ANÁLOGO GLP-2

10.4 EUROPE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.4.1 NORTH AMERICA

10.4.2 EUROPA

10.4.3 ASIA-PACIFIC

10.4.4 EAST MIDDLE Y AFRICA

10.4.5 SOUTH AMERICA

10.5 EUROPE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

10.5.1 ANTI-DIARRHEALS

10.5.2 PPIS

10.5.3 ANTÍTICOS

10.6 EUROPE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.6.1 NORTH AMERICA

10.6.2 EUROPA

10.6.3 ASIA-PACIFIC

10.6.4 Medio Oriente y ÁFRICA

10.6.5 SOUTH AMERICA

10.7 EUROPE ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

10.7.1 NORTH AMERICA

10.7.2 EUROPA

10.7.3 ASIA-PACIFIC

10.7.4 Aire acondicionado y ÁFRICA

10.7.5 SOUTH AMERICA

11 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE

11.1 Examen general

11.2 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

11.2.1 ACUTE PHASE (TYPE 1 SBS-IF)

11.2.2 FASE DE ADAPTACIÓN

11.2.3 FASE RECOVERY

11.3 EUROPA ACUTE PHASE (TYPE 1 SBS-IF) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.3.1 NORTH AMERICA

11.3.2 EUROPA

11.3.3 ASIA-PACIFIC

11.3.4 Medio Oriente y ÁFRICA

11.3.5 SOUTH AMERICA

11.4 EUROPEA ADAPTATION PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.4.1 NORTH AMERICA

11.4.2 EUROPA

11.4.3 ASIA-PACIFIC

11.4.4. EAST MIDDLE Y AFRICA

11.4.5 SOUTH AMERICA

11.5 EUROPE RECOVERY PHASE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

11.5.1 NORTH AMERICA

11.5.2 EUROPA

11.5.3 ASIA-PACIFIC

11.5.4 Medio Oriente y ÁFRICA

11.5.5 SOUTH AMERICA

12 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE

12.1 Examen general

12.2 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

12.2.1 ADULT

12.2.2 PEDIATRIC

12.3 EUROPE ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.3.1 NORTE AMERICA

12.3.2 EUROPA

12.3.3 ASIA-PACIFIC

12.3.4 Aire acondicionado

12.3.5 SOUTH AMERICA

12.4 EUROPE PEDIATRIC IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

12.4.1 NORTH AMERICA

12.4.2 EUROPA

12.4.3 ASIA-PACIFIC

12.4.4. EAST MIDDLE Y AFRICA

12.4.5 SOUTH AMERICA

13 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 Examen general

13.2 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

13.2.1 INTRAVENCION

13.2.2

13.2.3 ORAL

13.2.4 ENTERAL

13.3 EUROPE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

13.3.1 PN

13.3.2

13.4 EUROPE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.4.1 NORTE AMERICA

13.4.2 EUROPA

13.4.3 ASIA-PACIFIC

13.4.4 Aire acondicionado y ÁFRICA

13.4.5 SOUTH AMERICA

13.5 EUROPA SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.5.1 NORTE AMERICA

13.5.2 EUROPA

13.5.3 ASIA-PACIFIC

13.5.4 Medio Oriente y ÁFRICA

13.5.5 SOUTH AMERICA

13.6 EUROPA ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.6.1 NORTE AMERICA

13.6.2 EUROPA

13.6.3 ASIA-PACIFIC

13.6.4 Medio Oriente y ÁFRICA

13.6.5 SOUTH AMERICA

13.7 EUROPE ENTERAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

13.7.1 NORTH AMERICA

13.7.2 EUROPA

13.7.3 ASIA-PACIFIC

13.7.4 Medio Oriente y ÁFRICA

13.7.5 SOUTH AMERICA

14 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER

14.1 Examen general

14.2 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

14.2.1 HOSPITALS (ACUTE CARE)

14.2.2 Home CARE (Programas de HPN)

14.2.3 SETTINGS ICU

14.2.4 CENTROS PECIALTY GI

14.2.5 PEDIATRIC SPECIALTY HOSPITALS

14.3 EUROPA HOSPITALS (ACUTE CARE) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.3.1 NORTE AMERICA

14.3.2 EUROPA

14.3.3 ASIA-PACIFIC

14.3.4 Medio Oriente y ÁFRICA

14.3.5 SOUTH AMERICA

14.4 EUROPE HOME CARE (HPN PROGRAMS) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.4.1 NORTH AMERICA

14.4.2 EUROPA

14.4.3 ASIA-PACIFIC

14.4.4 ORIENTE MEDIO Y ÁFRICA

14.4.5 SOUTH AMERICA

14.5 EUROPE ICU SETTINGs in TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.5.1 NORTE AMERICA

14.5.2 EUROPA

14.5.3 ASIA-PACIFIC

14.5.4 Medio Oriente y ÁFRICA

14.5.5 SOUTH AMERICA

14.6 EUROPE SPECIALTY GI CENTERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.6.1 NORTE AMERICA

14.6.2 EUROPA

14.6.3 ASIA-PACIFIC

14.6.4 Medio Oriente y ÁFRICA

14.6.5 SOUTH AMERICA

14.7 EUROPE PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

14.7.1 NORTH AMERICA

14.7.2 EUROPA

14.7.3 ASIA-PACIFIC

14.7.4 Medio Oriente y ÁFRICA

14.7.5 SOUTH AMERICA

15 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 Examen general

15.2 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

15.2.1 HOSPITAL PHARMACY

15.2.2 PHARMACY ESPECIAL

15.2.3 RETAIL PHARMACY

15.2.4 PHARMACY ONLINE

15.3 EUROPE HOSPITAL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.3.1 NORTE AMERICA

15.3.2 EUROPA

15.3.3 ASIA-PACIFIC

15.3.4 ORIENTE MEDIO Y ÁFRICA

15.3.5 SOUTH AMERICA

15.4 EUROPE SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.4.1 NORTH AMERICA

15.4.2 EUROPA

15.4.3 ASIA-PACIFIC

15.4.4 ORIENTE MEDIO Y ÁFRICA

15.4.5 SOUTH AMERICA

15.5 EUROPE RETAIL PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

15.5.1 NORTE AMERICA

15.5.2 EUROPA

15.5.3 ASIA-PACIFIC

15.5.4 ORIENTE MEDIO Y ÁFRICA

15.5.5 SOUTH AMERICA

16 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION

16.1 EUROPA

16.1.1 ALEMANIA

16.1.2

16.1.3 FRANCIA

16.1.4

16.1.5 ESPAÑA

16.1.6 TURQUÍA

16.1.7 RUSSIA

16.1.8 NETHERLANDS

16.1.9 SUIZA

16.1.10 BELGIUM

16.1.11 SWEDEN

16.1.12 DENMARK

16.1.13 NORUEGA

16.1.14 FINLANDIA

16.1.15 Prueba de EUROPA

17 EUROPA EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY LANDSCAPE

17.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL

18 ANALISIS SWOT

19 PROFILES DE EMPRESA

19.1 FRESENIUS KABI

19.1.1 SNAPSHOT

19.1.2 ANÁLISIS REVENIDO

19.1.3 COMPANY SHARE ANALISIS

19.1.4 PRODUCTO PORTFOLIO

19.1.5 DESARROLLO RECIENTE

19.2 BAXTER INTERNATIONAL INC.

19.2.1 SNAPSHOT COMPANY

19.2.2 ANÁLISIS REVENIDO

19.2.3 COMPANY SHARE ANALISIS

19.2.4 PRODUCTO PORTFOLIO

19.2.5 DESARROLLO RECIENTE

19.3 NESTLÉ HEALTH SCIENCE

19.3.1

19.3.2 ANÁLISIS REVENIDO

19.3.3 COMPANY SHARE ANALISIS

19.3.4 PRODUCTO PORTFOLIO

19.3.5 DESARROLLO RECIENTE

19.4 LABORATORIAS ABBOTT

19.4.1

19.4.2 ANÁLISIS REVENIDO

19.4.3 COMPANY SHARE ANALISIS

19.4.4 PRODUCTO PORTFOLIO

19.4.5 DESARROLLO RECIENTE

19.5 TAKEDA PHARMACEUTICAL COMPANY LIMITADA

19.5.1 SNAPSHOT

19.5.2 ANÁLISIS REVENIDO

19.5.3 ANÁLISIS DE COMPANÍA

19.5.4 PRODUCTO PORTFOLIO

19.5.5 DESARROLLO RECIENTE

19.6 MOOG COMPANY

19.6.1 SNAPSHOT

19.6.2 ANÁLISIS REVENIDO

19.6.3 PRODUCTO PORTFOLIO

19.6.4 RECENT DEVELOPMENT/NEWS

19.7 ACULIFE HEALTHCARE

19.7.1

19.7.2 PRODUCTO PORTFOLIO

19.7.3 DESARROLLO RECIENTE

19.8 AMSINO INTERNATIONAL, INC

19.8.1 SNAPSHOT

19.8.2 PRODUCTO PORTFOLIO

19.8.3 DESARROLLO RECIENTE

19.9 AURORA

19.9.1

19.9.2 PRODUCTO PORTFOLIO

19.9.3 DESARROLLO RECIENTE

19.1 AMERIPHARMA Cuidado especial.

19.10.1 SNAPSHOT

19.10.2 PRODUCTO PORTFOLIO

19.10.3 DESARROLLO RECIENTE

19.11 Principales empresas de salud

19.11.1

19.11.2 ANÁLISIS REVENIDO

19.11.3 PRODUCTO PORTFOLIO

19.11.4 DESARROLLO RECIENTE

19.12 VELIGROSAS DIGESTIVE CARE

19.12.1

19.12.2 PRODUCTO PORTFOLIO

19.12.3 DESARROLLO RECIENTE

19.13 B. BRAUN SE

19.13.1

19.13.2 PRODUCTO PORTFOLIO

19.13.3 DESARROLLO RECIENTE

19.14 CAMVITTA

19.14.1

19.14.2 PRODUCTO PORTFOLIO

19.14.3 DESARROLLO RECIENTE

19.15 CHOICE PARENTERAL NUTRITION LLC

19.15.1

19.15.2 PRODUCTO PORTFOLIO

19.15.3 DESARROLLO RECIENTE

19.16 CONTINUUMRX

19.16.1

19.16.2 PRODUCTO PORTFOLIO

19.16.3 DESARROLLO RECIENTE

19.17 PHARMACEUTICAS

19.17.1

19.17.2 PRODUCTO PORTFOLIO

19.17.3 DESARROLLO RECIENTE

19.18 GRIFOLS S.A.

19.18.1

19.18.2 ANÁLISIS REVENIDO

19.18.3 PRODUCTO PORTFOLIO

19.18.4 DESARROLLO RECIENTE

19.19 PHARMACEUTICAS HIKMA

19.19.1

19.19.2 ANÁLISIS REVENIDO

19.19.3 PRODUCTO PORTFOLIO

19.19.4 DESARROLLO RECIENTE

19.2 HOSPIRA (PART OF PFIZER INC.)

19.20.1

19.20.2 ANÁLISIS REVENIDO

19.20.3 PRODUCTO PORTFOLIO

19.20.4 DESARROLLO RECIENTE

19.21 HANMI PHARM.CO.,LTD.

19.21.1

19.21.2 ANÁLISIS REVENIDO

19.21.3 PRODUCTO PORTFOLIO

19.21.4 DESARROLLO RECIENTE

19.22 MEDICAL DE UCI, INC.

19.22.1

19.22.2 ANÁLISIS REVENIDO

19.22.3 PRODUCTO PORTFOLIO

19.22.4 DESARROLLO RECIENTE

19.23 SOLUCIONES DE INFUSIÓN

19.23.1

19.23.2 PRODUCTO PORTFOLIO

19.23.3 DESARROLLO RECIENTE

19.24 SISTEMAS DE CARE INTEGRAADOS

19.24.1 SNAPSHOT

19.24.2 PRODUCTO PORTFOLIO

19.24.3 DESARROLLO RECIENTE

19.25 JEDUX PARENTERAL PRIVATE LIMITADA

19.25.1

19.25.2 PRODUCTO PORTFOLIO

19.25.3 DESARROLLO RECIENTE

19.26 LABORATOIRE DIELEN

19.26.1 SNAPSHOT COMPANY

19.26.2 PRODUCTO PORTFOLIO

19.26.3 DESARROLLO RECIENTE

19.27 NAPO THERAPEUTICS.

19.27.1

19.27.2 PRODUCTO PORTFOLIO

19.27.3 RECENT DEVELOPMENT/NEWS

19.28 NUTREGO

19.28.1 SNAPSHOT

19.28.2 PRODUCTO PORTFOLIO

19.28.3 DESARROLLO RECIENTE

19.29 NUTRICIA (Grupo de Dinamarca)

19.29.1 SNAPSHOT

19.29.2 ANÁLISIS REVENIDO

19.29.3 PRODUCTO PORTFOLIO

19.29.4 DESARROLLO RECIENTE

19.3 NUTRICIA NORTH AMERICA

19.30.1

19.30.2 PRODUCTO PORTFOLIO

19.30.3 DESARROLLO RECIENTE

19.31 NUTRISHARE

19.31.1

19.31.2 PRODUCTO PORTFOLIO

19.31.3 DESARROLLO RECIENTE

19.32 OXTHERA

19.32.1

19.32.2 PRODUCTO PORTFOLIO

19.32.3 DESARROLLO RECIENTE

19.33 PHARMKO, INC.

19.33.1

19.33.2 PRODUCTO PORTFOLIO

19.33.3 DESARROLLO RECIENTE

19.34 PUERTO LIFE SCIENCES PVT. LTD.

19.34.1 COMPANY SNAPSHOT

19.34.2 PRODUCTO PORTFOLIO

19.34.3 DESARROLLO RECIENTE

19.35 SHANDONG QIDU PHARMACEUTICAL CO., LTD.

19.35.1 SNAPSHOT COMPANY

19.35.2 PRODUCTO PORTFOLIO

19.35.3 DESARROLLO RECIENTE

19.36 Cuidado de la salud permanente

19.36.1

19.36.2 PRODUCTO PORTFOLIO

19.36.3 DESARROLLO RECIENTE

19.37 UF HEALTH

19.37.1

19.37.2 PRODUCTO PORTFOLIO

19.37.3 DESARROLLO RECIENTE

19.38 PHARMACEUTICAS IRONWOOD

19.38.1

19.38.2 ANÁLISIS REVENIDO

19.38.3 PRODUCTO PORTFOLIO

19.38.4 DESARROLLO RECIENTE

19.39 VISION PARENTERAL

19.39.1 COMPANY SNAPSHOT

19.39.2 PRODUCTO PORTFOLIO

19.39.3 DESARROLLO RECIENTE

19.4 ZEALAND PHARMA

19.40.1

19.40.2 ANÁLISIS REVENIDO

19.40.3 PRODUCTO PORTFOLIO

19.40.4 DESARROLLO RECIENTE

20 CUESTIÓN

21 INFORMES CONEXOS

Lista de Tablas

CUADRO 1 TREATMENTO DE LOS PACIENTES DEL OSE-IF

CUADRO 2 POBLACIONES PACIENTES ESTIMADAS

Cuadro 3

TABLE 4 KEY INDUSTRY INSIGHTS AND MARKET TRENDS IN THE EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET

TABLE 5 IMPACT OF WAR-DRIVEN DISRUPTIONS ON THE EUROPE TYPE 1 SBS-IF TREATMENT MARKET ECOSYSTEM AND INDUSTRY RESPONSE FRAMEWORK

CUADRO 6 DISTRIBUCIÓN DE PRODUCTOS Y PROYECTOS POR PHASE EUROPA TYPE 1 SBS-IF MARKET

CUADRO 7 DISTRIBUCIÓN DE LOS PROYECTOS POR APPROACH CIENTÍFICO Y FASE – EUROPA TYPE 1 SBS-IF MARKET

CUADRO 8 DISTRIBUCIÓN DE PROYECTOS POR EL AREA Y LA FASE THERAPEUTIC – EUROPE TYPE 1 SBS-IF MARKET

CUADRO 9 PIPELINE LANDSCAPE Y DESARROLLO CLINICO

CUADRO 10 TÉCNICAS BASADAS EN GLANCE R Pulido – EUROPA TYPE 1 MERCADO DE TRATAMIENTO SBS-IF

CUADRO 11 CANDIDATOS PRECLINICOS/RESEARCH

CUADRO 12 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

CUADRO 13 EUROPA NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 14 EUROPA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 15 EUROPA TOTAL PARENTERAL NUTRITION (TPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 16 EUROPA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 17 EUROPA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 18 EUROPA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 19 EUROPA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 20 EUROPA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 21 EUROPA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 22 EUROPA MACRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 23 EUROPA MICRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 24 EUROPA NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)

CUADRO 25 EUROPA THERAPY PHARMACOLOGICAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 26 EUROPA LA ADAPTACIÓN HORMONAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 27 EUROPA GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 28 EUROPA TERAPÍA DE HORMONE GROWTH EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 29 EUROPA IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 30 EUROPA ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 31 EUROPA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 32 EUROPA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 33 EUROPA PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 34 EUROPA ANÁLOGO SOMATOSTATIN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 35 EUROPA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 36 EUROPA SUPLEMENTE MICRONUTRIENT EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 37 EUROPA ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 38 EUROPA MEDIDAS DE ACID " ABSORPTION MODIFIERS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 39 EUROPA PUEBLO ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 40 EUROPA TERCERA PHARMACOLOGICA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)

CUADRO 41 EUROPA TREATMENTO SURGICO " INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

CUADRO 42 EUROPA PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE)

CUADRO 43 EUROPA OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 44 EUROPA TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 45 EUROPA TREATMENTO SURGICO " INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)

TABLE 46 EUROPE EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 47 EUROPA MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 48 EUROPA MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 49 EUROPE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 50 EUROPEO EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 51 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 52 EUROPA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 53 EUROPA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 54 EUROPA SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 55 EUROPA SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)

CUADRO 56 EUROPA ADJACENT / NON-SPECIFIC MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 57 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

CUADRO 58 EUROPA ACUTE PHASE (TYPE 1 SBS-IF) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 59 EUROPA ADAPTACIÓN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 60 EUROPA RECOVERY PHASE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 61 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 62 EUROPA ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 63 EUROPA PEDIATRIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 64 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 65 EUROPA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 66 EUROPA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 67 EUROPA SUBTANEOUS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 68 EUROPA ORAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 69 EUROPA ENTERAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 70 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

CUADRO 71 EUROPA HOSPITALS (ACUTE CARE) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 72 EUROPA INICIO CARE (Programas HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)

CUADRO 73 EUROPA TEMAS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 74 EUROPA ENTRE GI ESPECIAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 75 EUROPA PEDIATRIC SPECIALTY HOSPITALS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)

CUADRO 76 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 77 EUROPA HOSPITAL PHARMACY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 78 EUROPA PHARMACY ESPECIAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 79 EUROPA RETAIL PHARMACY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)

CUADRO 80 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)

CUADRO 81 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 82 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

CUADRO 83 EUROPA NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 84 EUROPA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 85 EUROPA TOTAL PARENTERAL NUTRITION (TPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 86 EUROPA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 87 EUROPA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 88 EUROPA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 89 EUROPA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 90 EUROPA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 91 EUROPA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 92 EUROPA MACRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 93 EUROPA MICRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 94 EUROPA THERAPY PHARMACOLOGICAL EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

CUADRO DE ADAPTACIÓN HORMONAL " INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 96 EUROPA GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 97 EUROPA TERAPÍA DE HORMONE GROWTH EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 98 EUROPA IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 99 EUROPA ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 100 EUROPA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 101 EUROPA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 102 EUROPA PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 103 EUROPA ANÁLOGO SOMATOSTATIN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 104 EUROPA H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 105 EUROPA SUPLEMENTE MICRONUTRIENT EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 106 EUROPA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 107 EUROPA MEDIDAS DE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 EUROPE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 109 EUROPA TREATMENTO SURGICO " INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

CUADRO 110 EUROPA PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE)

CUADRO 111 EUROPA OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 112 EUROPA TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 113 EUROPE EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 114 EUROPA MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 115 EUROPA MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 116 EUROPE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 117 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 118 EUROPA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 119 EUROPA SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 120 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

CUADRO 121 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 122 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 123 EUROPA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 124 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

CUADRO 125 EUROPA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 126 USD

TABLE 127 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 128 GERMANY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 129 GERMANY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 130 GERMANY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 131 GERMANY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 132 GERMANY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 133 GERMANY ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 134 GERMANY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 135 GERMANY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 136 GERMANY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 137 GERMANY MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 138 GERMANY MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 139 GERMANY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 140 GERMANY HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 141 GERMANY GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 142 GERMANY GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 143 GERMANY IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 144 GERMANY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 145 GERMANY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 146 GERMANY ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 147 GERMANY PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 148 GERMANY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 149 GERMANY H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 150 GERMANY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 151 GERMANY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 152 GERMANY BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 153 GERMANY BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 GERMANY SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 155 GERMANY INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 156 OSTOMÍA DE ALEMANIA " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 157 GERMANY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 158 GERMANY EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 159 GERMANY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 160 GERMANY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 161 GERMANY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 162 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 163 GERMANY CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 164 GERMANY SBS-IF ATRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 165 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 166 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 167 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 168 GERMANY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 169 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 170 GERMANY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 171 USD

CUADRO 172 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 173 U.K. NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 174 U.K. PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 175 U.K. TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 U.K. HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 177 U.K. HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 178 U.K. ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 179 U.K. TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 180 U.K. FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 181 U.K. PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 182 U.K. MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 183 U.K. MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 184 U.K. PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 185 U.K. HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 186 U.K. GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 187 U.K. GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 188 U.K. IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE)

TABLE 189 U.K. ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 190 U.K. OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 191 U.K. ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 192 U.K. PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 193 U.K. ANÁLOGO SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE , 2018-2033 (US$ THOUSAND)

CUADRO 194 U.K. H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 195 U.K. MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 196 U.K. ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

TABLE 197 U.K. BILE ACID & ABSORPERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 198 U.K. BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 199 TREATMENTO SURGICO " INTERVENTIONAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 200 U.K. INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 201 U.K. OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 202 U.K. TRANSPLANTATION INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 203 U.K. EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 204 U.K. REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 205 U.K. MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 206 U.K. GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 207 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 208 U.K. CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)

CUADRO 209 U.K. SBS-IF EN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 210 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 211 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 212 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 213 U.K. INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 214 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 215 U.K. TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 216 USD

TABLE 217 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 218 FRANCE NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 219 FRANCE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 220 FRANCE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 221 FRANCE HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 222 FRANCE HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 223 FRANCE ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 224 FRANCE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 225 FRANCE FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 226 FRANCE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 227 FRANCE MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 228 MICRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 FRANCE PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 230 FRANCE HORMONAL & INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 231 FRANCE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 232 FRANCE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 233 FRANCE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 234 FRANCE ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 235 FRANCE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 236 FRANCE ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 237 FRANCE PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 238 FRANCE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 239 FRANCE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 240 FRANCE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 241 FRANCE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 242 FRANCE BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 243 FRANCE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 244 FRANCE SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 245 FRANCE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 246 FRANCE OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 247 FRANCE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 248 FRANCE EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 249 FRANCE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 250 FRANCE MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 251 FRANCE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 252 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 253 FRANCE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 254 FRANCE SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 255 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 256 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 257 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 258 FRANCE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 259 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 260 FRANCE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 261 USD

TABLE 262 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 263 ITALY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 264 ITALY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 265 ITALY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 266 ITALY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 267 ITALY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 268 INTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 269 TUBE ITALY FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 270 ITALY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 271 ITALY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 272 MACRONUTRIENTES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 273 MICRONUTRIENTES ITALIAS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 274 ITALY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 275 ITALY HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 276 ARMAS ITALIA GLP-2 EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 277 ITALY GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 278 ITALIA IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 279 ITALY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 280 ITALY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 281 ITALIA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 282 ITALY PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 283 ANÁLOGO DE SOMATOSTATINA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE , 2018-2033 (US$ THOUSAND)

CUADRO 284 ITALIA H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 285 ITALY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 286 ITALY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 287 ITALY BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 288 SEQUESTRANTES DE ITALIA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 289 TREATMENTO SURGICO " INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 290 PROCEDIMIENTOS ITALIAS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)

CUADRO 291 OSTOMÍA DE ITALIA " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 292 ITALY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 293 TERAPÍAS DE ITALIA " AVANCED EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 294 ITALY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 295 ITALY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 ITALY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 297 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 298 ITALY CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 299 MERCADO ATRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 300 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 301 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 302 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 303 ITALIA INTRAVENOUS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 304 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 305 ITALY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 306 USD

CUADRO 307 ESPAÑA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

CUADRO 308 ESPAÑA NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 309 ESPAÑA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 310 SPAIN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 311 ESPAÑA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 312 ESPAÑA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 313 ESPAÑA NUTRICIÓN ENTERAL (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 314 ESPAÑA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 315 SPAIN FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 316 SPAIN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 317 MACRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 318 MICRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 319 SPAIN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 320 ESPAÑA HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 321 SPAIN GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 322 SPAIN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 323 ESPAÑA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 324 ESPAÑA ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 325 ESPAÑA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 326 ESPAÑA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 327 SPAIN PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 328 SPAIN SOMATOSTATIN ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 329 ESPAÑA H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 330 SPAIN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 331 SPAIN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 332 ACID DE ESPAÑA & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 333 SPAIN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 334 ESPAÑA SURGICA Y TRATAMIENTO INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 335 SPAIN INTESTINAL LENGTHENING PROCEDURES EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 336 ESPAÑA OSTOMY " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 337 TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 338 ESPAÑA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 339 SPAIN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 340 ESPAÑA MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 341 ESPAÑA GENE THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 342 ESPAÑA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 343 SPAIN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 344 ESPAÑA SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 345 ESPAÑA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

CUADRO 346 ESPAÑA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 347 ESPAÑA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 348 ESPAÑA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 349 ESPAÑA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

CUADRO 350 ESPAÑA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 351 USD

TABLE 352 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 353 TURKEY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 354 TURKEY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 355 TURKEY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 356 TURKEY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 357 TURKEY HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 358 TURQUÍA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 359 TURKEY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 360 TURKEY FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 361 TURKEY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 362 MACRONUTRIENTES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 363 MICRONUTRIENTES DE TURQUÍA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 364 TURKEY PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 365 TURKEY HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 366 TURKEY GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 367 TURKEY GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 368 TURKEY IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 369 TURKEY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 370 TURKEY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 371 TURKEY ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 372 TURKEY PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 373 TURKEY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 374 TURKEY H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 375 TURKEY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 376 TURKEY ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 377 TURKEY BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 378 TURKEY BILE ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 TREATMENTO SURGICO e INTERVENTIONAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 380 PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 381 TURKEY OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 382 TURKEY INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 383 TURKEY EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 384 TURKEY REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 385 TURKEY MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 386 TURKEY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 387 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 388 TURKEY CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 389 TURKEY SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 390 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 391 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 392 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 393 TURKEY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 394 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 395 TURKEY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 396 USD

CUADRO 397 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

CUADRO 398 RUSSIA NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 399 RUSSIA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 400 RUSSIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 401 RUSSIA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 402 RUSSIA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 403 RUSSIA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 404 RUSSIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 405 RUSSIA FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 406 RUSSIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 407 RUSSIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 408 RUSSIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 409 RUSSIA PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 410 RUSSIA HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 411 RUSSIA GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 412 RUSSIA GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USTED)

CUADRO 413 RUSSIA IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 414 RUSSIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 415 RUSSIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 416 RUSSIA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 417 RUSSIA PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 418 RUSSIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 419 RUSSIA H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 420 RUSSIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 421 RUSSIA ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)

TABLE 422 RUSSIA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 423 RUSSIA BILE ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 424 RUSSIA SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 425 RUSSIA INTESTINAL LENGTHENING PROCEDURES EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 426 RUSSIA OSTOMY " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)

CUADRO 427 RUSSIA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 428 RUSSIA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 429 RUSSIA MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 430 RUSSIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 431 RUSSIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 432 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 433 RUSSIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 434 RUSSIA SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 435 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

CUADRO 436 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 437 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 438 RUSSIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 439 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

CUADRO 440 RUSSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 441 USD

CUADRO 442 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

CUADRO 443 NETHERLANDS NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 444 NETHERLANDS PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 445 NETHERLANDS TOTAL PARENTERAL NUTRITION (TPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 446 NETHERLANDS HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 447 NETHERLANDS HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 448 NETHERLANDS ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 449 NETHERLANDS TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 450 NETHERLANDS FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 451 NETHERLANDS PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 452 NETHERLANDS MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 453 NETHERLANDS MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 454 NETHERLANDS PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 455 NETHERLANDS HORMONAL ' INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 456 NETHERLANDS GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 457 NETHERLANDS GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 458 NETHERLANDS IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 459 NETHERLANDS ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 460 NETHERLANDS OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 461 NETHERLANDS ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 462 NETHERLANDS PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 463 NETHERLANDS SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 464 NETHERLANDS H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 465 NETHERLANDS MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 466 NETHERLANDS ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 467 NETHERLANDS BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 468 NETHERLANDS BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 469 NETHERLANDS SURGICAL ' INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 470 NETHERLANDS INTESTINAL LENGTHENING PROCEDURES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 471 NETHERLANDS OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 472 NETHERLANDS INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 473 NETHERLANDS EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 474 NETHERLANDS REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 475 NETHERLANDS MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 476 NETHERLANDS GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 477 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 478 NETHERLANDS CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 479 NETHERLANDS SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 480 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

CUADRO 481 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 482 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 483 NETHERLANDS INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 484 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

CUADRO 485 NETHERLANDS TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 486 USD

TABLE 487 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 488 SWITZERLAND NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 489 SWITZERLAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 490 SWITZERLAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 491 SWITZERLAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 492 SWITZERLAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 493 SWITZERLAND ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 494 SUIZA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 495 SWITZERLAND FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 496 SWITZERLAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 497 MACRONUTRIENTES DE SUIZA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 498 MICRONUTRIENTES DE SUIZA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 499 DE SUIZA PHARMACOLOGICA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 500 SWITZERLAND HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 501 SWITZERLAND GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 502 SWITZERLAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 503 SWITZERLAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 504 SWITZERLAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 505 SWITZERLAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 506 SWITZERLAND ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 507 SWITZERLAND PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 508 SWITZERLAND SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 509 SWITZERLAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 510 SUPLEMENTACIÓN MICRONUTRIENT EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 511 SWITZERLAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 512 SWITZERLAND BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 513 SEQUESTRANTES DE SUIZA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 514 TREATMENT SURGICAL " INTERVENTIONAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 515 SWITZERLAND INTESTINAL LENGTHENING PROCEDURES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 516 SWITZERLAND OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 517 SWITZERLAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 518 SWITZERLAND EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 519 SUIZA MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 520 SWITZERLAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 521 SWITZERLAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 522 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 523 SWITZERLAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 524 SWITZERLAND SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 525 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 526 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 527 SUIZA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 528 SWITZERLAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 529 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 530 SWITZERLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 531 USD

TABLE 532 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 533 BELGIUM NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 534 BELGIUM PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 535 BELGIUM TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 536 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 537 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 538 BELGIUM ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 539 BELGIUM TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 540 BELGIUM FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 541 BELGIUM PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 542 MACRONUTRIENTES BELGIUM EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 543 BELGIUM MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 544 BELGIUM PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 545 BELGIUM HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 546 ANALOGÍAS BELGIUM GLP-2 EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 547 BELGIUM GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USTED)

CUADRO 548 BELGIUM IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 549 BELGIUM ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 550 BELGIUM OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 551 BELGIUM ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 552 BELGIUM PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 553 ANÁLOGO SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 554 BELGIUM H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 555 BELGIUM MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 556 BELGIUM ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)

TABLE 557 BELGIUM BILE ACID " ABSORPERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 558 BELGIUM BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 559 TREATMENTO SURGICANO BELGIUM EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 560 BELGIUM INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 561 BELGIUM OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)

TABLE 562 BELGIUM INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 563 BELGIUM EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 564 BELGIUM REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 565 BELGIUM MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 566 BELGIUM GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 567 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 568 BELGIUM CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 569 BELGIUM SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 570 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 571 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 572 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 573 BELGIUM INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 574 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 575 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 576 USD

TABLE 577 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 578 SWEDEN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 579 SWEDEN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 580 SWEDEN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 581 SWEDEN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 582 SWEDEN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 583 SWEDEN ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 584 SWEDEN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 585 SWEDEN FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 586 SWEDEN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 587 MACRONUTRIENTES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 588 MICRONUTRIENTS SWEDEN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 589 SWEDEN PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 590 SWEDEN HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 591 ANALOGOS SWEDEN GLP-2 EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 592 SWEDEN GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 593 SWEDEN IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 594 SWEDEN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 595 SWEDEN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 596 SWEDEN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 597 SWEDEN PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 598 SWEDEN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

CUADRO 599 H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 600 SUPLEMENTACIÓN MICRONUTRIENT EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 601 SWEDEN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 602 SWEDEN BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 603 SEQUESTRANTES DE ACID DE BILLO EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)

TABLE 604 SWEDEN SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 605 SWEDEN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 606 SWEDEN OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 607 TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 608 SWEDEN EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 609 MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 610 SWEDEN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 611 SWEDEN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 612 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 613 SWEDEN CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 614 SWEDEN SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 615 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 616 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 617 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 618 SWEDEN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 619 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 620 SWEDEN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 621 USD

TABLE 622 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 623 DENMARK NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 624 DENMARK PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 625 DENMARK TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 626 DENMARK HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 627 DENMARK HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 628 DENMARK ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 629 DENMARK TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 630 DENMARK FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 631 DENMARK PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 632 DENMARK MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 633 MICRONUTRIENTS DENMARK EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 634 DENMARK PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 635 DENMARK HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 636 DENMARK GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 637 DENMARK GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 638 DENMARK IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 639 DENMARK ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 640 DENMARK OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 641 DENMARK ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 642 DENMARK PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 643 DENMARK SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 644 DENMARK H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 645 DENMARK MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 646 DENMARK ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 647 DENMARK BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 648 DENMARK BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 649 DENMARK SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 650 DENMARK INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 651 DENMARK OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 652 DENMARK INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 653 DENMARK EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 654 DENMARK REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 655 DENMARK MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 656 DENMARK GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 657 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 658 DENMARK CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 659 DENMARK SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 660 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 661 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 662 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 663 DENMARK INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 664 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 665 DENMARK TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 666 USD THOUSAND

TABLE 667 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 668 NORWAY NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 669 NORWAY PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 670 NORWAY TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 671 NORWAY HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 672 NORWAY HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 673 NORUEGA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 674 NORWAY TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 675 NORWAY FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 676 NORWAY PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 677 MACRONUTRIENTES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 678 MICRONUTRIENTES NORUEGAS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 679 NORWAY PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 680 NORWAY HORMONAL ' INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 681 NORWAY GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 682 NORWAY GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 683 NORWAY IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 684 NORWAY ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 685 NORWAY OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 686 NORWAY ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 687 INHIBITORES DE PUMP NORUEGA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

TABLE 688 NORWAY SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 689 NORWAY H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 690 NORWAY MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 691 THERAPY ANTI-INFECTIVE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 692 NORWAY BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 693 NORWAY BILE ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 694 TREATMENTO SURGICO e INTERVENTIONAL NORWAY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 695 PROCEDIMIENTOS DE LENGTHENING NORWAY INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 696 OSTOMÍA DE NORUEGA " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 697 TRANSPLANTACIÓN INTESTINAL NORUEGA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 698 THERAPIES NORWAY EMERGING " ADVANCED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 699 MEDICINA REGENERATIVO DE NORUEGA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 700 NORWAY MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 701 NORWAY GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 702 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 703 NORWAY CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 704 NORWAY SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 705 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 706 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 707 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 708 NORWAY INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 709 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

CUADRO 710 NORWAY TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 711 USD

TABLE 712 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 713 FINLAND NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 714 FINLAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 715 FINLAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 716 FINLAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

CUADRO 717 FINLANDA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

TABLE 718 FINLAND ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 719 FINLAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 720 FINLAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 721 FINLAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 722 FINLAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 723 MICRONUTRIENTES FINLANDOS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 724 FINLAND PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 725 FINLAND HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 726 FINLAND GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 727 FINLAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

TABLE 728 FINLAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 729 FINLAND ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 730 FINLAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 731 FINLAND ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 732 FINLAND PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 733 FINLAND SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 734 FINLAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 735 FINLAND MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 736 FINLAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 737 FINLAND BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 738 FINLAND BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 739 TREATMENTO SURGICO e INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)

CUADRO 740 PROCEDIMIENTOS DE LENGTHENING FINLAND INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 741 FINLAND OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 742 FINLAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 743 FINLAND EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 744 FINLAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 745 FINLAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 746 FINLAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 747 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

TABLE 748 FINLAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 749 FINLAND SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 750 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 751 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 752 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

TABLE 753 FINLAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 754 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 755 FINLAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

CUADRO 756 USD

TABLE 757 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)

TABLE 758 REST OF EUROPE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 759 REST OF EUROPE PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 760 REST OF EUROPE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 761 REST OF EUROPE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 762 REST OF EUROPE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)

CUADRO 763 REST OF EUROPE ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 764 REST OF EUROPE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 765 REST OF EUROPE FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 766 REST OF EUROPE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 767 REST OF EUROPE MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 768 REST OF EUROPE MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 769 REST OF EUROPE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 770 REST OF EUROPE HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 771 REST OF EUROPE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 772 REST OF EUROPE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)

CUADRO 773 REST OF EUROPE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 774 REST OF EUROPE ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 775 REST OF EUROPE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 776 REST OF EUROPE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 777 REST OF EUROPE PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 778 REST OF EUROPE SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)

TABLE 779 REST OF EUROPE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 780 REST OF EUROPE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 781 REST OF EUROPE ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 782 REST OF EUROPE BILE ACID & ABSORPERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 783 REST OF EUROPE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 784 REST OF EUROPE SURGICAL & INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 785 REST OF EUROPE INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

CUADRO 786 REST OF EUROPE OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 787 REST OF EUROPE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 788 REST OF EUROPE EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 789 REST OF EUROPE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 790 REST OF EUROPE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 791 REST OF EUROPE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 792 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)

CUADRO 793 REST OF EUROPE CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 794 REST OF EUROPE SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 795 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)

TABLE 796 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)

TABLE 797 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

CUADRO 798 REST OF EUROPE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 799 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 800 REST OF EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

Lista de figuras

FIGURE 1 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: MULTIVARIVATE MODELING

FIGURE 10 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: PRODUCT TYPE TIMELINE CURVE

FIGURE 11 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: APPLICATION COVERAGE GRID

FIGURE 12 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION

FIGURE 13 FOUR SEGMENTS COMPRISE THE EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY (2025)

FIGURE 14 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 RISING SBS-IF PATIENT POPULATION IS EXPECTED TO DRIVE THE EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET DURING THE FORECAST PERIOD OF 2026 TO 2033.

FIGURE 16 NUTRITIONAL SUPPORT THERAPY is EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET IN 2026 & 2033

FIGURE 17 DECISIONES STRATEGIC

FIGURE 18 PESTEL ANALISIS

FIGURE 19 ANALISIS DROC

FIGURE 20 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY TREATMENT MODALITY, 2025

FIGURE 21 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY MARKET ATTRIBUTION, 2025

FIGURE 22 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY DISEASE MANAGEMENT PHASE, 2025

FIGURE 23 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY PATIENT TYPE, 2025

FIGURE 24 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025

FIGURE 25 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY END USER, 2025

FIGURE 26 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025

FIGURE 27 EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)

FIGURE 28 EUROPE EUROPE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)

Ver información detallada

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

¿Cuál es el tamaño actual de la Europa Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) ¿Mercadillo de tratamiento?

The Europe Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) El mercado de tratamiento fue valorado en USD 273.07 millones en 2025 y se prevé que alcanzará USD 449,10 millones en 2033, creciendo en un CAGR de 7,1% de 2026 a 2033.

¿Cuál es la tasa de crecimiento prevista de la Europa Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) ¿Mercadillo de tratamiento?

The Europe Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Se espera que el mercado de tratamiento crezca en un CAGR de 7,1% durante el período de previsión de 2026 a 2033, impulsado por la creciente prevalencia del síndrome de intestino corto, la creciente adopción de terapias nutricionales y farmacológicas avanzadas, y la creciente conciencia de los programas de rehabilitación intestinal.

¿Qué segmento domina el mercado de tratamiento de Europa tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal)?

El segmento de Terapia de Apoyo Nutricional dominó el mercado de tratamiento Tipo 1 SBS-IF, con una cuota de ingresos del 41,87% en 2025. Su liderazgo se atribuye a su papel esencial en el mantenimiento de la hidratación, la absorción de nutrientes y la estabilidad metabólica, convirtiéndolo en la piedra angular de la gestión de pacientes SBS-IF en fases agudas y de recuperación.

¿Cuáles son los principales factores de crecimiento de la Europa Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) ¿Mercadillo de tratamiento?

Los principales factores de crecimiento de la Europa Tipo 1 SBS-IF (Síndrome del Tazón corto con falla intestinal) El mercado de tratamiento incluye la creciente prevalencia de insuficiencia intestinal asociada a reseecciones intestinales y la creciente adopción de terapias de apoyo nutricional especializadas. El crecimiento del mercado está respaldado por avances en tratamientos biológicos, programas de rehabilitación intestinal en expansión e inversiones crecientes en investigación de enfermedades raras y atención al paciente.

Europa Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market

Tasa de crecimiento anual compuesta (CAGR) : 7.10 %

Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)Tamaño

Ámbito de presentación de informesTipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Europa Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal) Dinámica del mercado de tratamiento

Europa Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)

Europa Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Tipo 1 SBS-IF (Síndrome del intestino delgado con falla intestinal)

Últimos desarrollos en Europa Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal) Mercado de Tratamiento

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

Tabla de contenido

Lista de Tablas

Lista de figuras

Metodología de investigación

Personalización disponible

Preguntas frecuentes

Informes relacionados con la industria